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Abstract 
 Skeletal muscle-specific ERα appears to play important roles in regulating 
skeletal muscle glucose and lipid homeostasis. The overall aim of this dissertation was 
to determine whether skeletal muscle-specific ERα is critical for maintaining metabolic 
function under conditions of lipid overload. To further advance our understanding of 
skeletal muscle-specific ERα, this study integrated in vivo and in vitro loss-of-function 
approaches by generating a novel inducible skeletal muscle-specific ERα knockout 
mouse model (ERαKOism) and by silencing ERα in human myotubes using an 
adenovirus-driven ERαshRNA. The overarching hypothesis is that induced ablation of 
skeletal muscle-specific ERα increased the susceptibility to high fat diet (HFD)-induced 
metabolic dysfunction. ERαKOism mice exhibited similar adiposity after acute and 
chronic HFD treatments compared to WT mice, for both females and males. Indirect 
calorimetry revealed that energy expenditure was similar between female WT and 
ERαKOism mice, even when exposed to acute and chronic HFD treatments. Male 
ERαKOism mice exhibited minimally greater energy expenditure after chronic HFD 
treatment compared to male WT mice, regardless of diet. Spontaneous cage activity 
was similar between diet-matched WT and ERαKOism mice for both sexes, even after 
acute and chronic HFD treatment. Analysis of glucose dynamics revealed that female 
ERαKOism-HFD exhibited greater glucose intolerance than WT-HFD after chronic HFD 
treatment. Ex vivo skeletal muscle glucose uptake was similar between female WT and 
ERαKOism mice, although GLUT4 protein content was lower in skeletal muscle of female 
ERαKOism, regardless of diet. Markers of pro-inflammation were also elevated in female 
ERαKOism mice, regardless of diet. Analysis of mitochondrial respiratory capacity, 
oxidative phosphorylation efficiency, and H2O2 emission potential in permeabilized 
skeletal muscle fibers, revealed that skeletal muscle mitochondrial function was similar 
between WT and ERαKOism for both sexes. In human skeletal myotubes sourced from 
healthy and obese-insulin resistant adult women, ATP production rate was minimally 
lower in myotubes transduced with ERαshRNA compared to scrambled-shRNA (control) 
myotubes. Overall, the data suggest that skeletal muscle ERα is critical for maintaining 
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Chapter 1: Introduction and Specific Aims 
 
In most countries worldwide, the prevalence of the Metabolic Syndrome (MetS), 
continues to rise and is reported to be wide-ranging from ~10% to alarmingly ~50% of 
all adults within each country (Beltrán-Sánchez, Harhay, Harhay, & McElligott, 2014; J. 
Moore, Chaudhary, & Akinyemiju, 2017; O’Neill & O’Driscoll, 2015; Ranasinghe, 
Mathangasinghe, Jayawardena, Hills, & Misra, 2017). MetS comprises of at least 3 of 
the following conditions: excess adiposity, hypertriglyceridemia, insulin resistance, low 
high-density lipoprotein-cholesterol (HDL-C), high fasting blood glucose, and 
hypertension, thus making MetS a precursor to Type 2 Diabetes and other obesity-
associated diseases (Beltrán-Sánchez et al., 2014; J. Moore et al., 2017; O’Neill & 
O’Driscoll, 2015). Large amounts of stored body fat are associated with mechanisms 
that initiate the development of insulin resistance including lipotoxicity, a reduction in 
mitochondrial function, alterations in redox homeostasis, inflammation, and endoplasmic 
reticulum stress (Bosma, Kersten, Hesselink, & Schrauwen, 2012; Lark, Fisher-
Wellman, & Neufer, 2012; Muoio, 2014; Muoio & Neufer, 2012).  
Epidemiological evidence has documented that alterations in estrogen signaling 
can increase the risk of developing MetS  (Carr, 2003). A significant reduction in 
estrogen action in humans due to aging (e.g. menopause), surgical outcomes (e.g. 
oophorectomy) or genetic reasons (e.g. estrogen receptor polymorphisms) are 
associated with increased risk of MetS (Ahtiainen et al., 2012; Brussaard, Gevers 
Leuven, Frölich, Kluft, & Krans, 1997; Demir et al., 2008; Dørum et al., 2008; 
Efstathiadou et al., 2015; Gallagher et al., 2007; Lo, Zhao, Scuteri, Brockwell, & 
Sowers, 2006; Sites, Brochu, Tchernof, & Poehlman, 2001). Conversely, estrogen 
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therapy is associated with decreased adiposity and improved insulin sensitivity in 
postmenopausal women (Ahtiainen et al., 2012; Brussaard et al., 1997; Demir et al., 
2008; Sites et al., 2001). Collectively, the data suggest that estrogens protect the body 
from metabolic disease; however, the protective mechanisms induced by estrogen 
action remain largely undefined. 
Among the estrogen receptors that mediate estrogen signaling in cells, estrogen 
receptor-alpha (ERα) is thought to be critical in regulating skeletal muscle glucose and 
lipid homeostasis. Global ablation and conditional skeletal muscle-specific ablation of 
the gene that encodes for ERα (ESR1) results in significant increases in body fat, 
impaired whole body insulin sensitivity, skeletal muscle insulin resistance, increased 
markers of skeletal muscle inflammation, and altered mitochondrial health (Ribas et al., 
2010, 2016). Unfortunately, the utilization of global ERα knockout models does not allow 
the dissection of primary versus secondary effects because ERα is expressed in 
numerous tissues (Baltgalvis, Greising, Warren, & Lowe, 2010; Couse, Lindzey, 
Grandien, Gustafsson, & Korach, 1997; Drew et al., 2015; Khalid & Krum, 2016; H.-R. 
Lee, Kim, & Choi, 2012; Pugach, Blenck, Dragavon, Langer, & Leinwand, 2016; Yuchi 
et al., 2015). Furthermore, findings from current conditional skeletal muscle-specific 
ERα knockout models may be confounded by developmental effects. 
The current gap in the literature that this dissertation aimed to elucidate was the 
effect of skeletal muscle-specific ERα deletion in the adult animal on skeletal muscle 
metabolism and physiological function. This dissertation also sought to determine if 
estrogen/ERα signaling in adult skeletal muscle has a direct or indirect role in protecting 
against high fat diet-induced insulin resistance is still unclear. Thus, the overall purpose 
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of this dissertation was to determine whether skeletal muscle-specific ERα is critical for 
the regulation of skeletal muscle glucose and lipid homeostasis under acute and chronic 
lipid overload.  
 
Specific Aim #1:  
Determine whether skeletal muscle ERα is critical for maintaining metabolic function 
under acute exposure to a high fat diet (HFD).  
 
Hypothesis: Induced ablation of skeletal muscle-specific ERα in adult female and male 
mice increased the susceptibility to develop excess adiposity, impaired whole body 
metabolism, and glucose intolerance after an acute HFD. 
 
This study generated a novel inducible skeletal muscle-specific ERα knockout 
mouse model (ERαKOism) using the tamoxifen-inducible Cre-loxP system to avoid 
confounding developmental mechanisms that may have an impact on metabolism at 
adulthood. In this study, female and male ERαKOism mice grew and matured with 
normal ERα function. ERα was ablated when mice became young adults. To determine 
whether body composition was affected by the induced ablation of ERα, body mass, fat 
mass, and lean mass were measured at baseline and after a 1 week HFD. Indirect gas 
calorimetry was used to assess whether induced ablation of ERα affected whole body 
oxygen consumption, carbon dioxide production, energy expenditure, and flexibility in 
fuel selection at baseline and during the acute switch to a HFD. Finally, to assess 
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peripheral glucose dynamics, a glucose tolerance test was performed after a 1 week 
HFD.   
 
Specific Aim #2:  
Determine whether skeletal muscle ERα is critical for maintaining metabolic function 
under chronic exposure to a high fat diet (HFD).   
 
Hypothesis: Induced ablation of skeletal muscle-specific ERα in adult female and male 
mice increased the susceptibility to develop excess adiposity, impaired whole body 
metabolism, glucose intolerance, skeletal muscle insulin resistance, increased skeletal 
muscle inflammation, and reduced mitochondrial respiration after chronic HFD.  
 
Long-term exposure to a high fat diet results in the disruption of multiple 
mechanisms associated with maintaining normal insulin sensitivity. The response of 
ERαKOism mice to acute and chronic high fat diets may be different, further providing 
valuable insight on the importance of skeletal muscle-specific ERα in glucose and lipid 
metabolism. The aforementioned experiments in Specific Aim #1 were repeated after a 
12-week HFD. Additionally, ex vivo basal and insulin-stimulated skeletal muscle glucose 
uptake, markers of inflammation, and indices of mitochondrial function in skeletal 
muscle were assessed after the 12-week HFD treatment to comprehensively determine 




Specific Aim #3:   
Determine whether skeletal muscle ERα critical for maintaining mitochondrial respiration 
in human myotubes. 
 
Hypothesis: Induced ablation of skeletal muscle-specific ERα in human myotubes 
altered mitochondrial respiratory capacity. 
 
This study attempted to translate the results found in Specific Aim #2 to human 
skeletal muscle cells. In this study, primary human skeletal muscle cells, which were 
isolated from healthy and obese-insulin resistant adult women, were differentiated into 
mature myotubes. Mitochondrial respiratory capacity was assessed in myotubes 
transduced with ERαshRNA, which significantly reduced ERα expression.  
 
 
Chapter 2: Review of Literature 
 
The Metabolic Syndrome (MetS) is a global epidemic (Aguilar, Bhuket, Torres, 
Liu, & Rj, 2015; Amirkalali et al., 2015; J. Moore et al., 2017; O’Neill & O’Driscoll, 2015; 
Ranasinghe et al., 2017; Xiao et al., 2016). MetS is defined by the presence of at least 3 
of the following risk factors: abdominal obesity (waist circumference of ≥94cm in men, 
≥80cm in women), high fasting blood glucose (≥110mg/dl or ≥5.6mmol/L), 
hypertriglyceridemia (≥150mg/dl or ≥2mmol/L), low high-density lipoprotein-cholesterol 
(<40mg/dl in men, <50mg/dl in women), and hypertension (≥130/85mmHg) (O’Neill & 
O’Driscoll, 2015). While the pathogenesis of MetS and the exact mechanisms that link 
these risk factors are still currently being elucidated, the key components appear to be 
obesity and insulin resistance (Ervin, 2009; Ferrannini, Haffner, Mitchell, & Stern, 1991). 
Obesity, a consequence of nutrition overload coupled with a sedentary lifestyle, 
dramatically increases the susceptibility to insulin resistance and dyslipidemia (Rask-
Madsen & Kahn, 2012). Averting and/or treating MetS is critical to prevent more severe 
conditions linked to MetS such as Type 2 Diabetes Mellitus, cardiovascular disease, 
and metabolic disease-associated cancers (Esposito, Chiodini, Colao, Lenzi, & 
Giugliano, 2012; Goldberg & Mather, 2012; Kul et al., 2014; O’Neill & O’Driscoll, 2015; 
Rask-Madsen & Kahn, 2012; Samson & Garber, 2014).  
The prevalence of MetS is high in women and men with significantly reduced 
estrogen action; however, the etiology of this phenomenon remains poorly defined 
(Carr, 2003; Gallagher et al., 2007; M. Jones, Chin Boon, Proietto, & Simpson, 2006; Lo 
et al., 2006; Park et al., 2003; Pu, Tan, Yu, & Wu, 2017). Animal models have provided 
valuable insight on underlying mechanisms that affect glucose and lipid homeostasis 
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when estrogen action is impaired. This review summarizes our current understanding of 
how alterations in estrogen action influences the development of defining features of 
MetS, obesity and insulin resistance. 
 
Excess Adiposity and Insulin Resistance in Women and Men with Reduced 
Estrogen Action 
 
Reduced estrogen action occurs with natural menopause, surgical menopause, 
aromatase deficiency, and estrogen receptor polymorphisms, and these are all 
associated with obesity and insulin resistance.  
 
Natural Menopause 
Analyses of the National Health and Nutrition Examination Survey 
(NHANES) 1988-1994 data on US adults have revealed that postmenopausal 
status is a risk factor for MetS, independent from age, ethnicity, body mass index 
(BMI), smoking, drinking, physical activity level, and household income (Carr, 
2003; Park et al., 2003). Natural menopause is characterized by ovarian senescence 
and the absence of menstruation for ≥12 months. Circulating estrogen levels decline 
after menopause, which typically occurs when women reach ~51 years of age (Gold, 
2011). The most recent NHANES 2007-2012 data implies that the relationship between 
natural menopause and MetS continues to exist, wherein the prevalence of MetS is ~5-
10% in 18-29 year old women, ~35-55% in the 50-69 year age group, and ~45-70% in 
women over age 70, regardless of race and ethnicity (J. Moore et al., 2017). Cross-
sectional studies from different countries (e.g. Korea (Kim, Park, Ryu, & Kim, 2007), 
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India (Dasgupta et al., 2012), Nepal (Sapkota, Sapkota, Acharya, Raut, & Jha, 2015), 
Iran (Eshtiaghi, Esteghamati, & Nakhjavani, 2010; Maharlouei, Bellissimo, Ahmadi, & 
Lankarani, 2013), Brazil (Marchi et al., 2017), China (Chang et al., 2000), French 
(Trémollières, Pouilles, Cauneille, & Ribot, 1999), Taiwan (W. Y. Lin et al., 2006)) have 
also similarly documented that MetS is more prevalent in postmenopausal than pre-
menopausal women, even after adjusting for age. Longitudinal studies have further 
supported the notion that the development of MetS accelerates after menopause 
(Janssen, Powell, Crawford, Lasley, & Sutton-tyrrell, 2008; Lovejoy, Champagne, de 
Jonge, Xie, & Smith, 2008; Macdonald, New, Campbell, & Reid, 2003). Data from a 4-
year longitudinal study on premenopausal women (mean age of 43) have revealed that 
visceral fat, which is the adipose depot most associated with MetS development, 
significantly increases when women reach menopause (Lovejoy et al., 2008). 
Furthermore, these studies have also reported that abdominal obesity (as indicated by 
high waist circumference or body mass index) and insulin resistance (as indicated by 
high fasting blood glucose and hyperinsulinemia) significantly increases the risk of MetS 
development (Chang et al., 2000; Dasgupta et al., 2012; Ervin, 2009; Gaspard, 2009; 
Lovre & Mauvais-Jarvis, 2015; Park et al., 2003). However, some studies have 
documented that decreases in physical activity levels, resting energy expenditure, and 
age confound the association between postmenopausal status and MetS (Lovejoy et al., 
2008; Macdonald et al., 2003; Pandey et al., 2010). Nonetheless, the overwhelmingly 
high prevalence of obesity and insulin resistance in postmenopausal women, has led 
researchers to postulate that the reduced ovarian production of estrogens triggers the 





According to a recent meta-analysis, the risk of developing MetS is ~1.5 
fold higher with surgical menopause than natural menopause (Pu et al., 2017). 
Bilateral oophorectomy or the surgical removal of the ovaries abruptly leads to 
menopause due to the significant reduction in ovarian hormone production (Hendrix, 
2005). This procedure is typically performed in cases where surgery is the best option to 
prevent ovarian and breast cancer, and to alleviate severe endometriosis (Evans et al., 
2016; Greene et al., 2016; Hendrix, 2005). Oophorectomy is often performed together 
with a hysterectomy (Evans et al., 2016; B. J. Moore, Steiner, Davis, Stocks, & Barrett, 
2016). Annually, over ~200,000 women in the US have their ovaries removed (B. J. 
Moore et al., 2016). Oophorectomy reduces ovarian cancer risk by up to 80% and 
breast cancer risk by up to 50% in premenopausal women with breast cancer type 
susceptibility gene (BRCA) mutations (Marchetti et al., 2014; Rebbeck, Kauff, & 
Domchek, 2009). Indeed, cancer is linked to increased mutations that arise from the 
proliferative and genotoxic effects of estrogens (Mungenast & Thalhammer, 2014; 
Russo & Russo, 2004; E. Simpson & Santen, 2015). However, oophorectomy has its 
own consequences. The development of MetS is a major health concern with this 
procedure, along with osteoporosis and vasomotor symptoms (hot flashes, vaginal 
dryness, etc.). Indeed, data from 3549 women in the NHANES 1988-1994 study have 
revealed that women, who have undergone oophorectomy before menopause (<40 
years old), display greater waist circumference, skinfold thickness, and percent body fat 
than age-matched women with intact ovaries (A. M. McCarthy, Menke, & Visvanathan, 
2013). A longitudinal study has also shown that hyperglycemia is greater with surgical 
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menopause compared to natural menopause (Farahmand et al., 2014). Incident 
diabetes is also higher in women, who have undergone oophorectomy, than women 
with intact ovaries (Appiah, Winters, & Hornung, 2014). Obesity increases the risk of 
developing metabolic dysfunction associated with oophorectomy (A. M. McCarthy, 
Menke, Ouyang, & Visvanathan, 2012). Moreover, the risk of all-cause mortality in 
obese women is higher when oophorectomy is performed before rather than after the 
age of 40 (A. M. McCarthy et al., 2012). Collectively, the increased incidence of MetS 
associated with oophorectomy further supports the concept that the abrupt reduction of 




Case studies on aromatase deficient men and women suggest that 
aromatase deficiency is also associated with metabolic dysfunction (M. Jones et 
al., 2006). Aromatase, encoded by the CYP19A1 gene, is the enzyme that converts 
androgens to estrogens; therefore, genetic mutations of the CYP19A1 gene lead to 
estrogen deficiency. In contrast to natural or surgical menopause, reduced estrogen 
action due to aromatase deficiency is rare. However, the incidence of MetS is 
significantly high in aromatase deficient men (Carani et al., 1997; Z. Chen et al., 2015; 
Herrmann et al., 2002; M. Jones et al., 2006; Maffei et al., 2004; Morishima, Grumbach, 
Simpson, Fisher, & Qin, 1995). These case studies have reported increased abdominal 
adiposity, BMI (25-30 kg/m2), circulating triglycerides (~305mg/dl), fasting blood glucose 
(~180mg/dl), and the homeostasis model assessment of insulin resistance (HOMA-
IR=3.6, normally <2.4) (Carani et al., 1997; M. Jones et al., 2006). Aromatase deficiency 
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is also associated with Type 2 Diabetes and hepatic steatosis (Maffei et al., 2004). In 
addition, the onset of MetS is evident at a young age (mid-20s) in men, who have the 
CYP19 mutation (Carani et al., 1997; Morishima et al., 1995). Case studies, which have 
documented MetS in women with aromatase deficiency, are even more uncommon. 
Due to genital abnormalities and health complications since infancy, these women with 
the CYP19A1 mutation undergo surgeries and hormone therapy at an early age (as 
early as 22 months of age) (Morishima et al., 1995). These are performed to restore 
reproductive function and prevent the recurrence of ovarian cysts (Morishima et al., 
1995). Thus, early treatments to normalize hormone levels may have protected these 
women from MetS. However, a few case studies have documented that women 
diagnosed with aromatase deficiency and treated at a later age exhibit MetS (Gagliardi, 
Scott, Feng, & Torpy, 2014; Guercio et al., 2009). For example, a CYP19A1 mutation 
has been found in a 25yr old woman with central obesity (waist circumference of 
131cm), high fasting blood glucose (6.1mmol/L), high fasting insulin (57mU/L, normally 
<12mU/L), and impaired glucose tolerance (Gagliardi et al., 2014). Collectively, the high 
incidence of increased adiposity and insulin resistance in men and women with 
aromatase deficiency suggests that estrogens may have important metabolic functions 
in both sexes.  
 
Estrogen Receptor Mutations and Polymorphisms 
Men and women with reduced estrogen action due to certain estrogen 
receptor (ER) mutations and polymorphisms also have an increased risk of 
excess adiposity and insulin resistance. Estrogens exert their functions by initially 
binding to estrogen receptors. A case study in 1994 on a 28-year old man with a single 
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base pair mutation (cytosine-to-thymine transition) in the second exon (that results in a 
protein with no DNA- and ligand-binding domains) is the first to document an 
association between disrupted ER function and insulin resistance in a human (Smith et 
al., 1994). This man presented with moderately high fasting blood glucose levels 
(135mg/dl) and impaired glucose tolerance, despite having high insulin levels and high 
endogenous estradiol concentrations (Smith et al., 1994). By 2006, single nucleotide 
polymorphisms (SNPs) of the estrogen receptor-1 (ESR1) and -2 (ESR2) genes have 
been linked to MetS (Lo et al., 2006). For instance, ESR1 rs3798577 TT is associated 
with low insulin sensitivity in US-based Chinese women, and ESR2 rs1255998 CC and 
ESR2 rs1256030 CC are associated with MetS in US-based Chinese and Japanese 
women, respectively (Lo et al., 2006). These specific SNPs are not associated with 
MetS in Caucasian and African American women (Lo et al., 2006). However, many 
other SNPs within the intron 1-intron 2 regions of ESR1 are associated with Type 2 
Diabetes, MetS, and each of the components of MetS in African American men and 
women (Gallagher et al., 2007). Another study has shown that presenting with 3 or 
more polymorphic alleles is associated with lower human chorionic gonadotropin-
induced estradiol production (Anagnostou et al., 2013). One of the most studied ESR1 
SNPs located in intron 1 is the c.454-351 A>G (rs9340799), and is associated with 
MetS in African Americans (Gallagher et al., 2007). Moreover, the G allele of ESR1 
rs9340799 is associated with the presence of all components of MetS in premenopausal 
Egyptian women (Ghattas, Mehanna, Mesbah, & Abo-Elmatty, 2013) as well as total 
lipids and triglycerides in postmenopausal Brazilian women (Gomes-Rochette et al., 
2017). The minor C allele of another well-characterized ESR1 SNP in intron 1, c.454-
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397 T>C (rs2234693), is also associated with components of MetS in Egyptian women, 
except for waist circumference (Ghattas et al., 2013). Moreover, the C allele of 
rs2234693 is associated with high BMI in postmenopausal Caucasian women (Deng et 
al., 2000). Other pathologic conditions that are associated with rs9340799 and 
rs2234693 polymorphisms of ESR1 include infertility (Ayvaz, Ekmekçi, Baltacı, Önen, & 
Ünsal, 2009), breast cancer (Zhang et al., 2015), and cardiovascular disorders (Schuit 
et al., 2004; Shearman et al., 2003). Notably, these studies suggest that the relationship 
between particular ER polymorphisms and cellular dysfunction may be specific to one’s 
sex and/or ethnicity.  
 
Mechanisms that Link Obesity and Skeletal Muscle Insulin Resistance 
 
Insulin is a hormone secreted by the β cells of pancreas in response to changes 
in blood glucose levels. The major metabolic functions of insulin include the uptake of 
glucose in skeletal muscle, suppression of glucose production in the liver, and inhibition 
of adipose tissue lipolysis. In skeletal muscle, insulin binds to the insulin receptor on the 
sarcolemma, which triggers the phosphorylation of tyrosine residues on the β-subunit of 
the insulin receptor. The insulin receptor substrate-1 (IRS-1) subsequently moves to the 
sarcolemma, binding to the insulin receptor, which leads to the activation of the p85 
regulatory subunit and p110 catalytic subunit of phosphatidylinositol-3 (PI-3) kinase, and 
the increase in phosphatidylinositol-3,4,5 triphosphate. Subsequent docking of 
phosphoinositide-dependent protein kinase-1 (PDPK1) and protein kinase B (Akt) on 
the sarcolemma occurs. PDPK1 phosphorylates Akt, which then inactivates the Akt 
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substrate of 160kDa (AS160). In turn, this inactivates other GTPases involved in 
retaining glucose transporter-4 (GLUT4) in the cytosol. Once GLUT4 docks on the cell 
membrane, glucose enters the cell by facilitated diffusion. Normally, approximately 80-
90% of insulin-stimulated glucose uptake takes place in skeletal muscle while 5-10% 
occurs in adipose tissue (Thiebaud et al., 1982).  
Insulin resistance is defined as a condition wherein target tissues do not respond 
normally to insulin. As a result, blood glucose levels remain elevated in women and men 
with normal pancreatic beta cell function. Skeletal muscle insulin resistance, 
characterized by reductions in muscle glucose uptake in the presence of insulin, 
primarily affects the progression to Type 2 Diabetes Mellitus (DeFronzo & Tripathy, 
2009). Although insulin resistance develops with age (Halter et al., 2014), obesity due to 
excess caloric intake and physical inactivity significantly increases one’s susceptibility to 
impaired insulin sensitivity (O’Neill & O’Driscoll, 2015).  
This section will review mechanisms that have shed light to the link between 
excess adiposity and skeletal muscle insulin resistance. Three different mechanisms 
have been proposed: lipotoxicity, inflammation, and alterations in mitochondrial 
respiration and redox homeostasis (de Luca & Olefsky, 2008; Fisher-Wellman & Neufer, 
2012; Glass & Olefsky, 2012; Kitessa & Abeywardena, 2016; Muoio, 2014; Samuel, 
Petersen, & Shulman, 2010; Samuel & Shulman, 2016). 
 
Lipotoxicity 
Excess adiposity, which increases intramuscular lipid accumulation, is 
associated with impaired insulin signaling. The skeletal muscle can store a 
substantial amount of lipids, which functions as a fuel reserve (Schrauwen-Hinderling et 
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al., 2003). Intramyocellular lipids (IMCLs) are mostly composed of triacylglycerol (TAG), 
but also contain diacylglycerol (DAG), sphingolipids (e.g. ceramides), cholesterol esters, 
and free cholesterol. Energetic demand causes IMCLs to be oxidized in the 
mitochondria to produce ATP, the primary fuel for muscle contraction. IMCLs are more 
abundant in oxidative (Type 1) fibers than glycolytic (Type 2x/2b) fibers, and are 
attributed to the oxidative fiber’s greater capacity to oxidize and preferentially utilize fat 
as the substrate for ATP generation (Schrauwen-Hinderling, Hesselink, Schrauwen, & 
Kooi, 2006). Accordingly, increased IMCL accumulation is beneficial to the sport 
performance of healthy, insulin sensitive endurance athletes (Coen & Goodpaster, 
2012). However, excess IMCL deposition also occurs in non-athletic, overweight/ obese 
individuals and is associated with the development of insulin resistance (Amati, 2012). 
IMCL accumulation is thought to occur due to increased free fatty acid mobilization from 
adipose tissue to skeletal muscle in the absence of increased fat utilization (Blaak, 
2003). Studies on lipid-induced insulin resistance have documented that fatty acid re-
esterification into bioactive lipid intermediates – diacylglycerol (DAG) and ceramide – 
activate inflammatory or stress signaling complexes that decrease the activity of the 
insulin signaling pathway in skeletal muscle, consequently decreasing glucose uptake 
(Kitessa & Abeywardena, 2016). For example, previous studies have observed that 
DAG activates different isoforms of protein kinase C-θ, βII, δ (Itani, Ruderman, 
Schmieder, & Boden, 2002; M. Li, Vienberg, Bezy, O’Neill, & Kahn, 2015), which 
activates c-Jun N-terminal kinase (JNK). JNK suppresses insulin signaling by 
phosphorylating IRS-1 at the serine site (Ser307), and results in impaired GLUT4 
translocation towards the cell membrane and facilitation of glucose entry into the cell 
16 
 
(Aguirre, Uchida, Yenush, Davis, & White, 2000). Thus, glucose uptake is impaired in 
the presence of accumulated DAGs in skeletal muscle. Specific DAG species such as 
C16:0, C18:0, C18:1, C18:2, C20:4 DAGs are found to more strongly associate with 
insulin resistance (Szendroedi et al., 2014). Greater ceramide accumulation is also 
observed in C2C12 myotubes pre-treated with palmitate than untreated myotubes, 
which coincides with lower insulin-stimulated phosphorylation of Akt, lower basal and 
insulin-stimulated glucose uptake, lower phosphorylation of glycogen synthase kinase-
3, and lower glycogen synthesis (Schmitz-Peiffer, Craig, & Biden, 1999). One study has 
attributed the ceramide-associated reduction of phosphorylated Akt to the increased 
activity of a stress signaling kinase, protein kinase C-ζ (Hajduch et al., 2008). 
Dexamethasone treatment, which is known to increase ceramide accumulation, also 
leads to reductions in muscle glucose uptake (Holland et al., 2007). Conversely, 
myriocin treatment, a known inhibitor of ceramide synthesis, protects mice and rats from 
developing skeletal muscle insulin resistance (Holland et al., 2007; Kurek et al., 2015). 
Similar to DAG, measuring total ceramide does not always associate with insulin 
resistance. Specific long chain ceramide species such as C18:0 (Bergman et al., 2016), 
C20:1 and C22:0 ceramides (de la Maza et al., 2015) are reported to more strongly 
associate with a decline in insulin sensitivity. More studies are needed to define how 






Lipids induce skeletal muscle inflammation and is associated with insulin 
resistance. Myocytes isolated from obese insulin resistant individuals exhibit increased 
tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCP-1, also 
known as chemokine (C-C motif) ligand 2, CCL2) expression (Saghizadeh, Ong, 
Garvey, Henry, & Kern, 1996; Wu & Ballantyne, 2017). In turn, TNF-α and MCP-1 are 
thought to induce increased migration of immune cells that originate from lipid depots 
surrounding skeletal muscle, termed intermuscular and perimuscular adipose tissues 
(Wu & Ballantyne, 2017). These depots are reported to contain greater concentrations 
of pro-inflammatory factors compared to skeletal muscle (Khan et al., 2015; Wu & 
Ballantyne, 2017). Specifically, macrophage and T-cell infiltration in skeletal muscle are 
increased in non-diabetic obese insulin resistant and Type 2 diabetic individuals (Khan 
et al., 2015; Wu & Ballantyne, 2017). M1-macrophages are present in skeletal muscle, 
as indicated by the increase in interferon gamma (IFN-γ) expressing T-helper-1 (Th1) 
cells that have previously been shown to promote the M1-like phenotype (Khan et al., 
2015; Wu & Ballantyne, 2017). Increased M1-macrophages are consistently 
documented in adipose tissue during obesity and secrete pro-inflammatory cytokines 
such as TNF-α (Nguyen et al., 2007). Indeed, previous studies have demonstrated that 
overexpression of MCP-1 as well as incubation of myocytes with long chain saturated 
fatty acids increases M1-macrophages in skeletal muscle (Nguyen et al., 2007; 
Patsouris et al., 2014). Several studies have also shown that in myocytes, TNF-α 
activates the inhibitor of nuclear factor kappa-B kinase (IKK) complex, which leads to 
the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), 
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and in turn, the development of insulin resistance (De Alvaro, Teruel, Hernandez, & 
Lorenzo, 2004; Khan et al., 2015; Nguyen et al., 2007; Saghizadeh et al., 1996). 
Skeletal muscle inflammation coincides with increased serine phosphorylation of IRS-1 
(Rui et al., 2001), and reduced muscle glucose uptake (Wu & Ballantyne, 2017). Other 
studies have documented that the lipid-induced increase in TNF-α also activates JNK in 
skeletal muscle (Wu & Ballantyne, 2017). As eluded to earlier, previous studies have 
observed that JNK activity is elevated in skeletal muscle of obese individuals (Pal, 
Febbraio, & Lancaster, 2016) and in myocytes incubated with palmitate (Senn, 2006). 
JNK activity is associated with lipid-insulin resistance for JNKs impair insulin signaling 
by phosphorylating serine and threonine residues of IRS-1, resulting in reduced insulin 
action (Aguirre et al., 2000).  
 
Alterations in Skeletal Muscle Mitochondrial Respiration and Redox Homeostasis  
Alterations in skeletal muscle mitochondrial function are also linked to lipid-
induced insulin resistance. Some studies have observed that mitochondrial respiratory 
capacity, mitochondrial content, and expression of genes necessary for oxidative 
metabolism are lower in skeletal muscle of obese insulin resistant compared to healthy 
individuals (Lowell & Shulman, 2005; Mogensen et al., 2007). Others have found that 
skeletal muscle mitochondria of young adult, obese insulin resistant men exhibit 
increased H2O2 emission potential (E. J. Anderson et al., 2009; Fisher-Wellman et al., 
2014). Whether insulin resistance develops due to inherent mitochondrial dysfunction 
that leads to IMCL accumulation or due to chronic overnutrition that leads to increased 
H2O2 and altered redox homeostasis is still under debate.  
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Researchers have hypothesized that the onset of lipid-induced insulin 
resistance occurs with the inability of the mitochondria to cope with the presence 
of excess lipids, thus exhibiting an inflexibility to completely oxidize fat (Lowell & 
Shulman, 2005). Mitochondrial content and activity of key mitochondrial proteins are 
thought to be altered, reducing mitochondrial function (Lowell & Shulman, 2005; Morino, 
Petersen, & Shulman, 2006). Specifically, a reduction in mitochondrial respiratory 
capacity may cause the accumulation of lipid intermediates, which activates the 
cascade of events leading to impaired skeletal muscle glucose uptake (Morino et al., 
2006). For example, transport of mobilized free fatty acid from adipose tissue to skeletal 
muscle results in IMCL build up that is associated with reduced mitochondrial fat 
oxidation (Boyle, Zheng, Anderson, Neufer, & Houmard, 2012). In human permeabilized 
myotubes, state 3-supported mitochondrial respiration in the presence of a lipid 
substrate is significantly lower in the obese group compared to the lean group (Boyle et 
al., 2012). However, while there is substantial evidence that excess IMCL is associated 
to the development of insulin resistance, this is not always accompanied by reductions 
in the capacity of mitochondria to oxidize fat. Previous works have demonstrated that 
permeabilized skeletal muscle fibers of obese insulin resistant adults and high fat diet-
fed rodents with insulin resistance exhibit normal mitochondrial respiratory capacity (E. 
J. Anderson et al., 2009; Fisher-Wellman et al., 2014). In addition, certain mouse 
models, which can have reduced mitochondrial respiration, can exhibit normal glucose 
tolerance (Jackson et al., 2018). 
Alternatively, excess nutritional load can induce chronic elevations in 
skeletal muscle mitochondrial H2O2 production, thus altering the redox 
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environment and initiating the onset of insulin resistance (Fisher-Wellman & 
Neufer, 2012). Here, the electron transport system of the mitochondria receives excess 
hydrogen from reducing equivalents NADH and FADH2. As more hydrogen protons 
build-up in the intermembrane space, creating back pressure, the mitochondria relieves 
this pressure by generating superoxide (Fisher-Wellman & Neufer, 2012). Superoxide 
dismutases rapidly convert superoxide into H2O2 (Schieber & Chandel, 2014). Excess 
H2O2 can alter redox biology by oxidizing thiolate anions of cysteine (Schieber & 
Chandel, 2014). In turn, allosteric changes in proteins occur, modifying function or 
damaging proteins. The glutathione and thioredoxin redox buffering systems that 
scavenge H2O2 are also affected, which further contributes to the increasingly oxidized 
cellular environment (Fisher-Wellman & Neufer, 2012). Recent studies have 
demonstrated that skeletal muscle mitochondria of mice, which exhibit insulin resistance 
as a result of high fat diet exposure, display a lower reduced/oxidized glutathione ratio 
(Fisher-Wellman et al., 2016). The lower ratio indicates a reduction in the buffering 
capacity, which promotes prolonged exposure to elevated intracellular H2O2 (E. J. 
Anderson et al., 2009). Importantly, H2O2 emission potential is higher in these mice, but 
mitochondrial respiratory capacity is normal (E. J. Anderson et al., 2009; Fisher-
Wellman et al., 2014). The importance of H2O2 is confirmed when overexpressing 
catalase (the enzyme responsible for converting H2O2 to H2O) targeted to the 
mitochondria protects mice (MCAT mice) from high fat diet-induced insulin resistance 
(E. J. Anderson et al., 2009; Ryan et al., 2016). Previous works have demonstrated that 
elevations in H2O2 oxidize phosphatases, inactivating phosphatase function in inhibiting 
kinase activity (Fisher-Wellman & Neufer, 2012; Schieber & Chandel, 2014). 
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Subsequently, stress sensitive kinases are activated, which phosphorylate insulin 
signaling molecules, like IRS-1, at the serine site, reducing the activity of the insulin 
signaling cascade (Fisher-Wellman & Neufer, 2012). These data support the model 
where mitochondrial H2O2 links excess adiposity to insulin resistance by impairing 
insulin signaling. However, in contrast to this model, a recent study has demonstrated 
that MCAT mice are not protected from skeletal muscle insulin resistance induced by an 
acute lipid infusion (H. Y. Lee et al., 2017). The authors of the study have concluded 
that in some circumstances, insulin resistance occurs in the absence of elevated H2O2.  
 
Collectively, the etiology of lipid-induced insulin resistance is complex such that 
the underlying mechanisms: lipotoxicity, inflammation, and alterations in mitochondrial 
function and redox biology appear to be intertwined. Nonetheless, estrogens 
interestingly influence each of these mechanisms. The remaining sections of this review 
will discuss how estrogens have critical roles in regulating glucose and lipid 
homeostasis as well as mitochondrial function.  
 
Estrogens’ Protective Role against Obesity and Insulin Resistance 
 
Historically, ovarian extracts were used as early as the 1900s to alleviate 
menopausal symptoms due to the association between such vasomotor symptoms and 
bilateral removal of the ovaries (E. Simpson & Santen, 2015). Shortly after the discovery 
and isolation of estradiol in 1940 (E. Simpson & Santen, 2015), a pharmaceutical 
company, Wyeth, synthesized a complex of conjugated estrogens (CEE), named 
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Premarin, which was isolated from urine of pregnant mares (E. Simpson & Santen, 
2015; Vance, 2007). Premarin, which mostly constituted estrone sulfate and 10 other 
weak estrogen agonists (Pinkerton et al., 2017), became the main hormone therapy 
(HT) used to treat menopausal symptoms for many years in Canada and US until the 
1970s (Vance, 2007). Later on, CEE was also prepared in combination with synthetic 
forms of progesterone (e.g. medroxyprogesterone acetate) (CEE + P) (Pinkerton et al., 
2017). CEE and estradiol alleviated vasomotor symptoms to a similar extent (Pinkerton, 
Abraham, Bushmakin, Cappelleri, & Komm, 2016). 
The role of estrogens in maintaining metabolic homeostasis is documented 
in numerous reports that associate HTs with decreased adiposity (Ahtiainen et al., 
2012; Macdonald et al., 2003; Munoz, Derstine, & Gower, 2002; Pu et al., 2017; 
Salpeter et al., 2006; Sites et al., 2001) and increased insulin sensitivity (Ahtiainen et 
al., 2012; Brussaard et al., 1997; Demir et al., 2008; Munoz et al., 2002). A meta-
analysis of 107 trials in 2006 has revealed that HT lowers body fat percentage and 
HOMA-IR in postmenopausal women (Salpeter et al., 2006). HT also lowers HOMA-IR 
and improves the serum lipid profile in postmenopausal women with diabetes (Salpeter 
et al., 2006). More recently, a meta-analysis in 2017 has also revealed that 17β-
estradiol (E2) treatment lasting ≥3 months lowers total triglyceride levels, and CEE is 
beneficial in improving circulating lipoprotein profiles in postmenopausal women (Pu et 
al., 2017). The following randomized control trials provide strong evidence for the 
beneficial effects of HT on glucose and lipid metabolism. First, results of the 10-year 
follow-up on over ~48000 postmenopausal women in the 1976 Nurses’ Health Study 
show HT users to more likely have undergone oophorectomy, be leaner, and less likely 
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to be diabetic compared to non-users (Stampfer et al., 1991). Second, data from the 
1987 Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial on 875 healthy 
postmenopausal women (45-64 years old) have also revealed that CEE and CEE + P 
improve fasting glucose levels (Miller et al., 1995). Third, the Women’s Health Initiative 
(WHI), the largest randomized control trial on HT (n= ~160,000 postmenopausal 
women), has documented that HT (CEE and CEE + P) lowers the incidence of Type 2 
Diabetes (Manson et al., 2013). Moreover, a 7-year longitudinal study on 907 women 
transitioning to their postmenopausal years has shown that HT (CEE and CEE + P) 
users exhibit lower BMI and body weight than non-users (Macdonald et al., 2003). The 
only study on monozygotic twins discordant for estrogen therapy has also observed that 
long term estrogen therapy (CEE and CEE + P) users (~7.5 years, range 2-16 years) 
display lower adiposity, lower fasting serum glucose levels, and lower glycated 
hemoglobin (HbA1c) levels than their identical co-twin non-users (Ahtiainen et al., 
2012). Estrogen pills also lower body fat in women who have undergone oophorectomy 
(A. M. McCarthy et al., 2013), and transdermal estradiol lowers triglyceride levels, fat 
accumulation in the liver, fasting glucose and insulin levels in aromatase deficient men 
(Carani et al., 1997; Maffei et al., 2004). Overall, these studies provide evidence for the 
notion that raising estrogens to physiological levels can ameliorate the detrimental 
effects of natural and surgical menopause as well as aromatase deficiency on adiposity 





Risks of Hormone Therapy  
 
Previous observational and randomized control trial studies have revealed 
that HT increases cancer and cardiovascular disease risk, making HT a 
controversial form of treatment. Studies in the 1970s have reported that Premarin 
(CEE) increases the risk of endometrial cancer, especially with long term use (≥7 years) 
(Ziel & Finkle, 1975). Low and high doses of unopposed CEE also increase the risk of 
simple or complex endometrial hyperplasia (Furness et al., 2012; Herrington et al., 
2000), which may in turn, lead to endometrial cancer. CEE + P (e.g. Prempro) is 
currently regarded as an equally effective but safer drug in alleviating vasomotor 
symptoms, as it diminishes the risk of endometrial hyperplasia and cancer (Furness et 
al., 2012; Vance, 2007). Data from the 10-year follow-up on the 1976 Nurses’ Health 
Study have shown that very high doses of HT (i.e. 1.25mg/day) increase the risk of 
coronary heart disease (Stampfer et al., 1991). Notably, ~71% of ~48,000 women in the 
Nurses’ Health Study used unopposed CEE, only ~3% were on CEE + P, and only ~4% 
of the cohort were prescribed a dosage of ≥1.25mg/day (Stampfer et al., 1991). The 
study that convinced the United States of America to significantly decrease the use of 
HT is the only large-scale randomized control trial, called the Women’s Health Initiative 
(WHI) (Vance, 2007). The WHI has revealed that unopposed CEE is associated with a 
higher incidence of stroke (HR, 1.39; 95% CI, 1.10-1.77) and total cardiovascular 
disease (arterial and venous) (HR, 1.12; 95% CI 1.01-1.24) in women who have 
undergone a hysterectomy (G. Anderson et al., 2004). Moreover, CEE + P is associated 
with the increased incidence of coronary heart disease (HR, 1.29; 95% CI, 1.02-1.63), 
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stroke (HR, 1.41; 95% CI, 1.07-1.85), pulmonary embolism (HR, 2.13; 95% CI, 1.39-
3.25), and breast cancer (HR, 1.26; 95% CI, 1.00-1.59) in postmenopausal women with 
an intact uterus (Rossouw et al., 2002). These findings have led to the untimely end of 
the WHI for the risks outweighed the beneficial reduction in the incidence of hip 
fractures and Type 2 Diabetes (G. Anderson et al., 2004; Manson et al., 2013; Rossouw 
et al., 2002). Since then, the deliberation on whether or not HT should still be prescribed 
continues to this day. Substantial benefits of HT on adiposity and insulin sensitivity may 
outweigh the risks, but this depends on the individual’s age, number of years past the 
onset of menopause, and the presence of other health contraindications (Pinkerton et 
al., 2017). More recent studies, which re-analyzed the WHI data, have reported that 
healthy women within 10 years of menopause and younger than 60 years of age can 
safely use HT (Pinkerton et al., 2017). The data suggest that the incidence of 
myocardial infarction, total cancer (all types), and all-cause mortality is lower in the CEE 
and CEE + P groups than the placebo group in women who are 50-59 years of age 
(Manson et al., 2013). The absolute risk of adverse events with CEE and CEE + P is 
also lower in 50-59 year old women than 70-79 year old women (Manson et al., 2013). 
Finally, the risk of coronary heart disease is not significantly different between CEE or 
CEE + P and placebo users in 50-59 year old women whereas the excess risk is high in 
70-79 year old women with moderate to severe vasomotor symptoms (CEE HR, 4.34; 
95% CI, 1.43-13.14 and CEE + P HR, 5.79; 95% CI, 1.29-25.97) (Manson et al., 2013).  
The most recent Position Statement of the North American Menopause Society in 2017 
highlight that HT prescription must be individualized (Pinkerton et al., 2017). Overall, HT 
provides beneficial effects on metabolic health. However, the type, dose, and duration 
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of HT in conjunction with age, postmenopausal status, and medical history must all be 
considered in order to minimize the risks associated with HT (Pinkerton et al., 2017). 
The challenge today is to develop safer therapies that target specific tissues 
involved in the regulation of adiposity and insulin sensitivity in men and women with 
reduced estrogen action. The goal is to prevent accelerated adiposity and insulin 
resistance without increasing the risk for breast cancer, endometrial cancer, and 
cardiovascular disease. Thus, deciphering estrogens’ mechanisms of action in 
regulating glucose and lipid metabolism in insulin sensitive tissues is critical in 
advancing the field.  
 
Estrogens’ Mechanism of Action 
 
Estrogens are a class of steroid hormones. The 3 main forms of endogenous 
estrogens in humans are estrone (E1), 17β-estradiol (E2), and estriol (E3). Two 
scientists, Edward Doisy and Adolf Butenandt, independently but simultaneously, 
purified estrone from urine of pregnant women in 1929 (E. Simpson & Santen, 2015). 
Later on, Doisy purified estriol in 1931 and estradiol in 1940 (E. Simpson & Santen, 
2015). The Nobel Prize was given to Butenandt in 1939 for his discovery of estrone 
along with testosterone while Doisy was awarded his Nobel Prize in 1943, but for the 
purification of vitamin K (E. Simpson & Santen, 2015). E2 is the predominant and most 
potent form of endogenous estrogen (Kuhl, 2005). Estrogens, from both gonadal and 
extragonadal sites, exert their effects through genomic and non-genomic signaling (Cui, 
Shen, & Li, 2013).  
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Estrogens are primarily synthesized in the ovaries, and their production 
periodically rises and falls as part of the menstrual cycle. Menstrual cyclicity begins 
at ~12.4 years old (Chumlea et al., 2003) and ends at the age of ~51 years old 
(Greendale, Lee, & Arriola, 1999). The menstrual cycle is typically 28 days long and is 
divided into menstrual phases (Reed & Carr, 2015). Granulosa cells in the ovary 
synthesize estrogens by aromatase cytochrome P450 action, which converts circulating 
C19 androgens, testosterone and androstenedione, to estrogens (N. G. Anderson & 
Lieberman, 1980; Labrie, 2015; E. R. Simpson, 2003). Estrogens released into 
circulation are low during the early follicular phase (days 1-7) and progressively 
increase during the late follicular phase as the size of the follicle increases (days 9-14) 
(Reed & Carr, 2015). Ovulation typically occurs on day 14 and the succeeding days 
after ovulation are part of the luteal phase. During the mid-luteal phase (days 20-25), 
circulating estrogen levels remain higher than their concentrations during the early 
follicular phase and then eventually decline on days 26-28 when the egg is not fertilized 
(Reed & Carr, 2015). This menstrual cycle keeps occurring until the last menstrual 
period (often referred to as menopause). This postmenopausal stage in a woman’s life 
occurs naturally and is characterized by senescent ovaries that are no longer able to 
produce estrogens (E. R. Simpson, 2003). In contrast to humans, female rodents 
experience the estrous cycle beginning at ~4-6 weeks of age, which lasts 4-5 days 
(Nelson, Felicio, Randall, Sims, & Finch, 1982). In a typical estrous cycle, circulating 
estrogen levels peak during proestrus, declines during estrus, remains low during 
metestrus, and once again increases during diestrus (Walmer, Wrona, Hughes, & 
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Nelson, 1992). Cyclicity ends at ~18 months of age; however, ovary secretions cease in 
mice around ~24 months of age (Mobbs, Gee, & Finch, 1984).  
Men and postmenopausal women produce estrogens in extragonadal 
tissues. Estrogens are also synthesized in the mesenchymal cells of adipose tissue, 
breast, osteoblasts and chondrocytes of bone, the vascular endothelium, and aortic 
smooth muscle cells, brain, liver, adrenal glands, and skeletal muscle (Barakat, Oakley, 
Kim, Jin, & Ko, 2016; Longcope, Pratt, Schneider, & Fineberg, 1978; E. R. Simpson, 
2003). The estrogen concentrations produced from these tissues and cells are 
considerably lower compared to ovarian production of estrogens; however, studies have 
demonstrated that extragonadal estrogens exert important paracrine and intracrine 
effects (E. R. Simpson, 2003). For instance, some suggest that the development of 
postmenopausal breast cancer is more tightly associated with the estradiol 
concentrations in breast tissue than the low levels of circulating estrogens (E. R. 
Simpson, 2003). 
In genomic signaling, estrogens regulate the expression of target genes by 
binding to estrogen receptors-alpha (ERα) and beta (ERβ), which subsequently 
enable the receptors to bind to the target DNA. ERα and ERβ are two different 
receptors. The gene for ERα is ESR1, and is located on chromosome 6q25.1 in humans 
(Menasce, White, Harrison, & Boyle, 1993) and chromosome 10 in mice (Sluyser, 
Rijkers, de Goeij, Parker, & Hilkens, 1988). On the other hand, the gene for ERβ is 
ESR2 and is located on chromosome 14q22-24 in humans (Enmark et al., 1997) and 
chromosome 12 in mice (Tremblay et al., 1997). They are primarily known as nuclear 
receptors that act as transcription factors and signal transducers (Murphy, 2011). These 
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receptors contain 6 functional domains (A-F), similar to other members of the 
superfamily of nuclear receptors (Ruff, Gangloff, Marie Wurtz, & Moras, 2000). ERs 
have an A/B domain at the N-terminal region that has an activation function-1 (Ruff et 
al., 2000). ERα and ERβ have relatively different A/B domains (only 17% homology) 
(Enmark et al., 1997). The C domain contains the DNA-binding region, which is highly 
conserved between ERα and ERβ (97% homology) (Enmark et al., 1997). The D 
domain links the C to the E domain, which is the ligand-binding domain and contains an 
activation function-2 (Ruff et al., 2000). The ligand-binding domains of ERα and ERβ 
are ~59% homologous (Enmark et al., 1997). Lastly, the F domain is located at the C-
terminal region and serves as an extension of the ligand binding domain (Ruff et al., 
2000). Estrogens are bound to carriers in circulation (sex hormone binding globulin and 
albumin) and are lipophilic, allowing the spontaneous dissociation from the carriers and 
passive diffusion into the cell. Genomic signaling initially begins with the dissociation of 
chaperone proteins (heat shock protein-90, heat shock protein-70, and other proteins) 
from the ERs in the cytosol when estrogens enter the cell (Oren, Fleishman, Kessel, & 
Ben-Tal, 2004). Estrogens bind to the ligand-binding domain of ERs, which trigger the 
translocation of these estrogen-ER complexes to the nucleus (Raam et al., 1983). Once 
in the nucleus, the DNA-binding domain of ER binds to the estrogen response element 
(ERE) within the promoter region of the target gene, modulating gene expression 
(Driscoll et al., 1998; Klinge, 2001). Indeed, ERs mainly localize in the nucleus (Pugach 
et al., 2016; Yuchi et al., 2015). ERα is highly expressed in the uterus and ovaries, but 
are also found in the prostate stroma, testes, epididymis, breast, skeletal muscle, 
hypothalamus, pituitary, liver, pancreas, adipose, heart, bone, lungs, and blood vessels 
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(Baltgalvis et al., 2010; Couse et al., 1997; Drew et al., 2015; Khalid & Krum, 2016; H.-
R. Lee et al., 2012; Pugach et al., 2016; Yuchi et al., 2015). ERβ is highly expressed in 
ovaries, but are also found in the prostate epithelium, testes, epididymis, bone marrow, 
hypothalamus, adipose, lungs, bone, and blood vessels (Couse et al., 1997; Dieudonné, 
Leneveu, Giudicelli, & Pecquery, 2004; Enmark et al., 1997; Khalid & Krum, 2016; H.-R. 
Lee et al., 2012). Furthermore, estrogens can also exert their effects on genes that do 
not have ERE. About 1/3 of genes that are influenced by estrogens do not have ERE 
(O’Lone, Frith, Karlsson, & Hansen, 2004). Here, the ER binds to transcription factors 
such as activator protein-1 (AP-1) and specificity protein-1 (SP-1), acting as cofactors 
(Safe & Kim, 2008). For example, ER/SP-1 plays a role in the differentiation, 
proliferation, and survival of breast cancer cells by regulating estrogen-dependent 
genes like insulin-like growth factor-binding protein-4 and Cathepsin D (Safe & Kim, 
2004). ER/AP-1 also plays a role in breast cancer cell growth by regulating E2F 
transcription factor-1 and cAMP-dependent protein kinase inhibitor β (Dahlman-Wright 
et al., 2012; Safe & Kim, 2008). Other estrogen responsive genes that are regulated by 
ER through this indirect genomic signaling pathway include insulin like growth factor-1, 
Cyclin D1, low density lipoprotein receptor, and progesterone receptor (O’Lone et al., 
2004). 
ERs can also localize on the plasma membrane and exert the effects of 
estrogens through non-genomic signaling pathways, albeit there are less 
membrane ERs than nuclear ERs (Levin, 2009b; Razandi, Pedram, Greene, & Levin, 
1999). These membrane ERs have been initially identified in the 1970s (Pietras & 
Szego, 1977; E. Simpson & Santen, 2015), but have been more recently confirmed by 
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experiments with estrogen-linked dendrimer conjugates (EDCs), which cannot enter the 
nucleus (Harrington et al., 2006), and mutations inhibiting palmitolyation (Acconcia, 
Ascenzi, Fabozzi, Visca, & Marino, 2004; Adlanmerini et al., 2014). For example, one 
study in mice has shown that reendothelialization after carotid injury is similar between 
EDC and estradiol treatment (Adlanmerini et al., 2014). Previous studies have also 
demonstrated that palmitoylation is required for ER localization on the membrane 
(Acconcia et al., 2004; Adlanmerini et al., 2014). Upon estrogen stimulation, ERs can 
activate rapid signaling pathways, such as mitogen-activated protein kinase (MAPK), 
phosphoinositide-3 kinase/protein kinase B (PI3-K/Akt), and Gαi coupled protein 
signaling (E. Simpson & Santen, 2015). For instance, in breast cancer cells, estrogen 
binding to membrane-bound ERα can trigger the subsequent binding of ERα to MAPK 
(Song et al., 2002). Upon MAPK activation, ERα-MAPK translocates to the nucleus, 
where they can bind to either ERE or activate other transcription factors like nuclear 
receptor coactivator-3, nuclear receptor interacting protein-1, E1A binding protein p300, 
and cAMP responsive element binding protein-1 (E. Simpson & Santen, 2015). Notably, 
a key characteristic of non-genomic estrogen signaling is its rapid (within minutes) 
effects compared to genomic signaling (may take several hours) (Rainville, Pollard, & 
Vasudevan, 2015). Apart from full-length membrane-bound ERs (ERα-66kDa and ERβ-
56kDa) (Razandi et al., 1999), alternative splicing of ERα appears to promote 
palmitoylation, resulting in membrane localization and non-genomic signaling (L. Li, 
Haynes, & Bender, 2003; A. H. Y. Lin et al., 2013). Immunohistochemistry experiments 
of the 36-kDa ERα isoform (ERα36) have revealed that this isoform is primarily localized 
in the cytoplasm and plasma membrane in human breast cancer tissue (L. M. J. Lee et 
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al., 2008). A previous study has demonstrated that membrane-bound ERα36 induces 
calcium mobilization in breast cancer cells (Kang et al., 2010). In endothelial cells, 46-
kDa ERα (ERα46) localization has been observed in the nucleus, cytosol, and plasma 
membrane (L. Li et al., 2003). Membrane-bound ERα46 in endothelial cells activates 
NOS through the c-Src-PI3-K/Akt pathway (L. Li et al., 2007, 2003). Furthermore, a G-
protein coupled estrogen receptor (GPR30, now called GPER) is argued to be an 
estrogen receptor as well. GPER is a plasma membrane-bound receptor that is thought 
to mediate estrogen-driven non-genomic function through rapid kinase signaling 
(Prossnitz & Hathaway, 2015). For example, GPER mediates breast cancer cell growth 
via MAPK and PI3-K/Akt pathways (Prossnitz & Hathaway, 2015). However, whether 
GPER is truly an estrogen receptor is still under debate. Some studies have 
demonstrated that GPER activates membrane ERs, and that these membrane ERs are 
the receptors that activate downstream non-genomic signaling (Kang et al., 2010; Levin, 
2009a).  
 
Regulation of Glucose and Lipid Homeostasis by Estrogens: Effects on Adipose, 
Liver, and Skeletal Muscle Based on Animal Models of Reduced Estrogen Action  
 
The following animal models of reduced estrogen action: aromatase knockout, 
ovariectomized model, and global ER knockout models provide evidence for the 





Global genetic ablation of the aromatase enzyme (ARKO) leads to 
increased body fat and insulin resistance in both females and males. Aromatase is 
the enzyme responsible for converting testosterone to estradiol. Thus, the global loss of 
aromatase function leads to estrogen deficiency. Previous studies have found that 
female and male ARKO mice exhibit greater percent body fat and gonadal fat mass 
than wild-type (WT) mice by ~ 50-60% at 3 months of age, and progressive fat mass 
gain continues as these mice age (M. E. Jones et al., 2000; Takeda et al., 2003). Not 
surprisingly, adipocyte volume and adipocyte size are higher in both female and male 
ARKO mice by ≥50% at 4 months of age, and serum triglyceride levels are higher at 1 
year of age than WT mice (M. Jones et al., 2006; M. E. Jones et al., 2000). ARKO mice 
also exhibit severe hepatic steatosis at 2-3 months of age, which is up to 7-fold greater 
than in WT mice (Amano et al., 2017; M. Jones et al., 2006; M. E. Jones et al., 2000; 
Takeda et al., 2003). Indeed, lipogenic enzymes such as fatty acid synthase, acetyl 
coenzyme A carboxylase α, fatty acid transporter adipocyte differentiation-related 
protein are higher in ARKO than WT mice (M. Jones et al., 2006). Another study has 
demonstrated that fatty acid beta-oxidation activity is impaired in liver of male ARKO 
mice, which is accompanied by a reduction in liver very long chain fatty acyl-CoA 
synthetase, peroxisomal acyl-CoA oxidase, and medium-chain acyl-CoA 
dehydrogenase (Egawa, Toda, Nemoto, & Ono, 2003). Male ARKO mice also develop 
insulin resistance, as indicated by hyperinsulinemia and marked insulin intolerance at 4-
5 months of age (Takeda et al., 2003). Glucose tolerance is normal in male ARKO mice 
at 3 months of age, but is impaired by the 6th month of age (Takeda et al., 2003). 
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Furthermore, insulin signaling, as indicated by p-Akt protein content, is impaired in the 
liver, but not in adipose or skeletal muscle of ARKO mice (Van Sinderen et al., 2015). 
Three-week and 12-week estradiol treatments prevent excess fat mass gain (M. E. 
Jones et al., 2000), and improve glucose and insulin tolerance in male adult ARKO mice 
(Takeda et al., 2003). Similarly, female ARKO mice treated with estradiol for 6 weeks 
exhibit lower gonadal and omental fat mass, liver triglycerides, lower fasting insulin, and 
higher liver insulin signaling than untreated ARKO mice, all of which are improved to 
levels that are similar to WT (Van Sinderen et al., 2015). Collectively, estradiol 




Ovariectomized rodents consistently develop obesity and insulin 
resistance. The surgical removal of the ovaries (OVX), which is the primary organ that 
produces estrogens, leads to increased adiposity and insulin resistance (Camporez et 
al., 2013; Jackson et al., 2013; Wohlers & Spangenburg, 2010). The OVX model is most 
commonly used to study the effects of the reduction in estrogens in women, who have 
undergone natural or surgical menopause. Our laboratory has shown that at eight 
weeks post-OVX, OVX mice exhibit greater body weight, visceral and subcutaneous fat 
mass, intramuscular lipid content, and monounsaturated fatty acid accumulation in the 
liver (Jackson et al., 2011, 2013; Wohlers, Powers, Chin, & Spangenburg, 2013; 
Wohlers & Spangenburg, 2010). OVX mice consume similar amounts of food compared 
to sham-operated mice (SHAM); however, spontaneous cage activity and energy 
expenditure are lower in OVX than SHAM mice, which partially explain the greater fat 
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mass accumulation in OVX mice (Witte, Resuehr, Chandler, Mehle, & Overton, 2010). 
We have also shown that triglyceride and diglyceride concentrations in the liver are 
similar between SHAM and OVX mice at 8 weeks post-surgery (Valencia et al., 2016). 
However, one study has documented that OVX mice exhibit hepatic steatosis at 3 
months post-surgery (Rogers, Perfield, Strissel, Obin, & Greenberg, 2009). Our 
previous data have also indicated that OVX mice exhibit impaired insulin 
responsiveness in skeletal muscle fibers compared to sham-operated mice (Wohlers et 
al., 2013). Another study has shown that over a longer period of time (i.e. 26 weeks 
after ovariectomy), OVX mice remain insulin resistant (Vieira Potter et al., 2012). High 
fat diet treatment (HFD) exacerbates this obese and insulin resistant metabolic 
phenotype of OVX mice (Camporez et al., 2013). Although the ovary secretes other 
proteins and hormones, estrogen treatment (E2) lowers fat mass and improves glucose 
tolerance, insulin signaling in skeletal muscle, and fasting insulin levels (Riant et al., 
2009). Notably, results from a hyperinsulinemic-euglycemic clamp study has indicated 
that whole body insulin sensitivity is reduced in OVX mice while estradiol-treated OVX 
mice exhibit markedly improved insulin sensitivity that is similar to SHAM mice 
(Camporez et al., 2013). Furthermore, systemic insulin resistance is attributed to a 
decline in skeletal muscle insulin sensitivity (Camporez et al., 2013). OVX rats also 
display a similar obese and insulin resistant phenotype and respond similarly to 
estradiol treatment (Abbas & Elsamanoudy, 2011; Ainslie et al., 2001). However, OVX 
rats exhibit hyperphagia (Witte et al., 2010), which does not closely translate to the 
eating habits of postmenopausal women. Nonetheless, the data clearly show that 
significantly reduced levels of estrogens by ovariectomy leads to metabolic dysfunction. 
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Global ERα Knockout 
The global ERα knockout mouse model (ERαKO) recapitulates the obese 
and insulin resistant phenotype, which suggests that ERα is critical for the 
regulation of lipid and glucose metabolism. Previous studies have documented that 
adult female and male ERαKO mice exhibit ~20% greater body weight and ~50-60% 
greater fat mass than age-matched WT mice under both standard chow and long term 
high fat diet treatments, even though both groups consume similar amounts of food 
(Bryzgalova et al., 2006; Heine, Taylor, Iwamoto, Lubahn, & Cooke, 2000; Ohlsson et 
al., 2000; Ribas et al., 2010). Consistent with the increase in overall adiposity, ERαKO 
mice display greater amounts of skeletal muscle triglycerides, diglycerides, and 
ceramides than WT mice (Ribas et al., 2010). Energy expenditure and spontaneous 
cage activity are also lower in ERαKO compared to WT mice (Ribas et al., 2010). 
Additionally, ERαKO mice exhibit lower mRNA expression of fatty acid oxidation 
markers (peroxisome proliferator activated receptor-α, peroxisome proliferator activated 
receptor-δ, and uncoupling protein-2) compared to WT mice, which likely implies a 
reduction in skeletal muscle oxidative metabolism (Ribas et al., 2010). Pro-inflammatory 
signaling markers such as TNFα and p-JNK are also elevated in skeletal muscle and 
adipose tissue of ERαKO mice (Ribas et al., 2010). Excessive ectopic lipid 
accumulation in skeletal muscle is associated with cellular stress and activation of 
inflammatory signaling pathways, which are thought to impair insulin signaling, glucose 
uptake, and insulin sensitivity (Erion & Shulman, 2010; Holland et al., 2007; Schmitz-
Peiffer et al., 1999). Indeed, one study has documented that ERα ablation results in the 
development of skeletal muscle insulin resistance, with minor but detectable onset of 
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hepatic insulin resistance (Ribas et al., 2010). Data from the hyperinsulinemic-
euglycemic clamp have indicated that the insulin-stimulated glucose disposal rate, a 
marker for skeletal muscle insulin sensitivity, is 40% lower in ERαKO than WT mice 
(Ribas et al., 2010). This is supported by the ~50-65% reduction in insulin-induced 
activation of signaling molecules (pIRS-1tyr, p85 subunit of IRS-1-associated PI3-kinase, 
and pAktser473) in skeletal muscle (Ribas et al., 2010). Furthermore, skeletal muscle 
glucose uptake ex vivo is lower in ERαKO compared to WT mice (Bryzgalova et al., 
2006). Reports on skeletal muscle glucose transporter-4 (GLUT4), the main glucose 
transporter for glucose uptake in skeletal muscle, have been mixed. Some studies have 
shown lower GLUT4 protein content in ERαKO mice (R. Barros, Gabbi, Morani, Warner, 
& Gustafsson, 2009; R. Barros, Machado, Warner, & Gustafsson, 2006) while another 
study has reported similar GLUT4 protein content between ERαKO and WT mice (Ribas 
et al., 2010). In contrast, another hyperinsulinemic-euglycemic clamp study has 
provided evidence for marked hepatic insulin resistance in female and male ERαKO 
mice, such that the endogenous glucose output is ~50% higher than in WT mice despite 
high basal insulin levels (Bryzgalova et al., 2006). Moreover, these ERαKO mice only 
display modest skeletal muscle insulin resistance (Bryzgalova et al., 2006). A recent 
study has demonstrated the importance of considering the molecular domains of ERα 
(Handgraaf et al., 2013). ERα has 2 separate activation functions, AF-1 (A/B domain) 
and AF-2 (E domain), that can act synergistically or independently in order to mediate 
the transcription of target genes (Tora et al., 1989). When mice lacking whole body AF-
2 (ERαAF-2KO) are compared to ERαAF-1KO mice, the results suggest that ERαAF-2 
is necessary for normal lipid and glucose metabolism while ERαAF-1 is not required 
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(Handgraaf et al., 2013). ERαAF-2KO female and male mice exhibit increased adiposity 
and insulin resistance while ERαAF-1KO mice display no metabolic phenotype 
(Handgraaf et al., 2013). Moreover, ovariectomized ERαAF-2KO mice treated with 
estrogen are not protected from high fat diet-induced insulin resistance, unlike ERαAF-
1KO mice (Handgraaf et al., 2013). Additionally, global membrane-only ERα (MOER) 
and nuclear-only ERα (NOER) mouse studies have revealed that both pools of ERα are 
required to prevent excess adiposity (Pedram, Razandi, Blumberg, & Levin, 2016). ERα 
of MOER mice contains a ligand binding domain that is specifically targeted to the 
plasma membrane. As a result, MOER mice do not express ERα in the nucleus 
(Pedram et al., 2016). On the other hand, NOER mice have a point mutation C451A that 
does not permit palmitoylation; therefore, the mice only express ERα in the nucleus. 
Interestingly, both mice exhibit greater body weight and visceral fat than WT mice 
(Pedram et al., 2016). Moreover, estradiol treatment on isolated bone marrow stem cells 
(BMSCs) from WT mice inhibits cell differentiation into adipocytes (Pedram et al., 2016). 
This inhibitory effect is lost in BMSCs from NOER and MOER, which suggest that partial 
loss of ERα increases the susceptibility to form new adipocytes (Pedram et al., 2016). 
Membrane ERα also inhibits carbohydrate response element-binding protein-α and -β in 
differentiated 3T3-L1 (murine adipocyte-like cells) via AMPK and PKA, and in turn, 
inhibits the lipogenic enzymes, acetyl-CoA carboxylase and fatty acid synthase (Pedram 
et al., 2016). Overall, the loss of ERα significantly affects metabolic homeostasis. The 
disparity for the primary source of insulin resistance between studies calls for more 
tissue-specific estrogen receptor knockout models in order to advance our 
understanding of ERα function.  
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Global ERβ Knockout 
Global ERβ knockout mice (ERβKO) do not exhibit increased adiposity or 
impaired peripheral insulin sensitivity. A previous study has shown that body weight 
and fat mass are similar between adult ERβKO and WT mice (Bryzgalova et al., 2006). 
ERβKO mice are also protected from high fat diet-induced insulin resistance and ectopic 
lipid deposition, even though ERβKO mice exhibit greater body weight and adiposity 
than WT mice after 12 weeks of high fat diet treatment (Foryst-Ludwig et al., 2008). 
Furthermore, double ERα and ERβ knockout (ERα/βKO) mice display significantly 
increased visceral fat mass that is similar to age-matched ERαKO mice (Ohlsson et al., 
2000). Thus, it appears that ERβ is not necessary for preventing metabolic dysfunction.  
 
Global GPER Knockout 
The metabolic phenotype of the GPERKO mouse is currently unclear. Some 
investigators have reported that genetic ablation of GPER (GPERKO) in mice leads to 
obesity (Haas et al., 2009; Sharma et al., 2013) while others have documented no 
significant differences in adiposity between GPERKO and WT mice. (Isensee et al., 
2009; Martensson et al., 2009). Some studies have shown that adult GPERKO mice 
also display impaired glucose tolerance due to reduced pancreatic secretion of insulin in 
(Martensson et al., 2009), while others have observed that GPERKO mice exhibit 
normal glucose tolerance, similar to WT mice (Isensee et al., 2009). Indeed, GPER 
function in metabolism remains elusive since the reported effects of GPERKO depend 
on the genetic strain background of the animal models. Other investigators have even 
contested that GPER is not an estrogen receptor since the binding affinity of estrogen to 
GPER is low, classic ER antagonists (e.g. ICI182780) act as a GPER agonist, and 
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finally, all established GPERKO mouse models have normal reproductive function, in 
contrast to global ERαKO and ERβKO models  (Levin, 2009a; Otto et al., 2008). 
 
 
Regulation of Glucose and Lipid Homeostasis by Adipose-, Liver-, and Skeletal 
Muscle-Specific ERα: Evidence from Animal Models 
 
Effects of the significant reduction in estrogens or the global reduction of ERα 
function in both females and males support the notion that estrogens play an important 
role in protecting both sexes from the development of obesity and insulin resistance. 
However, global ERα knockout studies are not able to fully determine how ERα 
mediates the regulation of lipid and glucose metabolism. These studies have yielded 
critical information, but have been unable to determine tissue-specific effects since ERα 
is expressed at various levels across most tissues in the body. Specifically, ERα 
ablation alters multiple organ systems confounding the ability to determine the 
mechanistic function of tissue-specific ERα. These mouse models exhibit numerous 
alterations in peripheral tissue function, making it challenging to differentiate primary 
versus secondary effects. Research on tissue-specific functions of ERα are currently 
underway. Generation of tissue-specific ERα knockout models have allowed the 
possibility of determining which metabolic tissue is primarily affected by the loss ERα. 
Thus far, only conventional tissue-specific models of in vivo ERα ablation have been 
developed. The following section will discuss our current understanding of the role of 




Adipose-specific ERα Knockout 
Adipose tissue-specific ablation of ERα increases adiposity, adipose tissue 
inflammation, and fibrosis. Researchers have investigated the role of adipose tissue 
ERα in metabolism using 2 conventional adipose tissue-specific ERαKO mouse models 
that utilize either the adiponectin promoter driven-Cre recombinase (AdipoERαKO) 
(Davis et al., 2013) or the aP2-Cre recombinase (FERKO) (Drew et al., 2015). Four and 
a half month old AdipoERαKO mice exhibit ~60% less ERα expression than the WT 
while adult FERKO mice display a ~90% reduction in ERα. Gonadal fat mass and 
adipocyte size are greater in both adipose tissue-specific ERαKO mouse models. 
Glucose tolerance is not affected in female AdipoERαKO, but male AdipoERαKO are 
glucose intolerant. This finding suggests that adipose-specific ERα does not modulate 
glucose homeostasis in female mice. Fasting glucose and insulin levels are also not 
affected in female and male FERKO mice. Adipose tissue inflammation and fibrosis also 
manifest in a sex-specific manner. Macrophage infiltration marker F4/08 and pro-
inflammatory markers TNFα, toll-like receptor-4, and serum amyloid A-3 are ~80-90% 
greater in adipose tissue of male AdipoERαKO than their WT counterpart, but are not 
elevated in female AdipoERαKO mice. In male AdipoERαKO, inflammation is 
accompanied by increased lysyl oxidase and collagen type-VI expression, which are 
markers of adipose tissue fibrosis. Additionally, data from the offspring of the 
AdipoERαKO-global ERβKO cross-breed have revealed that ERβ has an important 
synergistic role with adipose ERα in the regulation of inflammation and fibrosis (Davis et 
al., 2013). The loss of ERβ impairs glucose tolerance in female AdipoERα/ERβKO mice, 
but not in male AdipoERα/ERβKO mice. ERβ loss also additively exacerbates adipose 
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tissue inflammation in male AdipoERα/ERβKO. Female AdipoERα/ERβKO mice also 
display greater inflammation and fibrosis in adipose tissue. 
 
Liver-specific ERα Knockout 
Deletion of liver-specific ERα by conventional conditional knockout yields 
different results from temporal induced knockdown in adult mice. Liver-specific 
ERαKO (LERαKO) studies have examined whether liver ERα plays a role in liver lipid 
deposition and insulin-stimulated suppression of endogenous glucose production, both 
of which are negatively affected in models of reduced estrogen action (OVX, ARKO, 
and global ERαKO) (Bryzgalova et al., 2006; Camporez et al., 2013; Egawa et al., 2003; 
Rogers et al., 2009). Current LERαKO mice are generated using the Cre-loxP approach 
under the liver-specific albumin promoter (Han et al., 2014; Matic et al., 2013). LERαKO 
mice exhibit little to no liver-specific ERα since birth, with about a ~90% and 99% 
reduction in liver ERα mRNA (Esr1) and protein content, respectively (Matic et al., 
2013). Adult female and male LERαKO mice are similar to age-matched WT mice in 
body weight, whole body and liver adiposity, glucose tolerance, and insulin signaling in 
the liver (Matic et al., 2013). Expression of known hepatic regulators of metabolism that 
are influenced by estrogen: sterol regulatory element binding transcription factor-1, 
stearoyl-coenzyme A desaturase-1, and glucose-6-phosphatase (G6Pase) (Han et al., 
2014; Jackson et al., 2011) are not affected by the loss of liver ERα (Matic et al., 2013). 
Furthermore, a 5-month HFD treatment in LERαKO mice does not exacerbate the 
glucose intolerance or elevated fasting insulin levels typically observed in WT-HFD mice 
(Matic et al., 2013). These effects are not a result of compensatory increases in ERβ 
and GPER expression. The authors have concluded that the metabolic phenotype of 
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mouse models with reduced estrogen action is not likely due to the loss of liver ERα. 
However, a recent study has demonstrated that liver-specific ERα knockdown by 
injection of adeno-associated virus-Cre (driven by the liver-specific thyroid binding 
globulin promoter) in 2-3 month old male ERα floxed mice (AAV-LERαKO), results in 
hepatic steatosis and elevated fasting glucose after 1 month post-injection of AAV (Qiu 
et al., 2017). Although body weight is not affected, the liver of AAV-LERαKO mice 
exhibit ~50% greater triglyceride deposition than WT mice, which is attributed to greater 
expression of de novo lipogenic markers, fatty acid synthase and acetyl-coa 
carboxylase-1. AAV-LERαKO mice also display high fasting glucose, which is in part, 
due to ~50% higher expression of gluconeogenic enzymes, G6Pase and 
phosphoenolpyruvate carboxykinase-1 (Pck1), than WT mice. This finding indicates that 
glucose production is less suppressed in AAV-LERαKO mice. In primary hepatocytes 
sourced from WT mice, estradiol-ERα has been demonstrated to directly bind to 
G6Pase and Pck1, both of which contain estrogen response element half-sites in their 
promoter region, and thus, inhibit G6Pase and Pck1 expression (Qiu et al., 2017). 
Indeed, estradiol treatment does not modulate G6Pase and Pck1 in primary 
hepatocytes from AAV-LERαKO mice (Qiu et al., 2017). No studies on liver-specific 
ERα in adult female mice have been conducted. Collectively, the data intriguingly 
suggest that liver ERα is critical in maintaining glucose and lipid homeostasis in male 
adult mice, but is not essential during development. More studies are needed to 
investigate the similarities and differences between embryonic and induced knockout of 
tissue-specific ERα function, its underlying mechanisms, and whether these functions 




Skeletal Muscle-specific ERα Knockout 
Ablation of skeletal muscle-specific ERα results in excess adiposity and 
significant skeletal insulin resistance. The skeletal muscle is the primary site for 
postprandial insulin-stimulated glucose uptake, lipid and glucose utilization, as well as a 
site for lipid storage (Thiebaud et al., 1982). Skeletal muscle ERα is, therefore, a 
potential potent regulator of glucose and lipid homeostasis. Thus far, only one study has 
utilized a skeletal muscle-specific ERαKO mouse model (MERKO), which is generated 
using the Cre-loxP approach, driven by the muscle creatine kinase promoter (Ribas et 
al., 2016). Adult female MERKO mice exhibit greater body mass due to 2.75-fold 
greater gonadal fat mass than WT mice. Skeletal muscle lipid deposition is also evident, 
wherein triglyceride, diglyceride, and ceramide levels are ~40-50% greater than WT 
mice. Markers of inflammation, p-JNK and p-IKKβ are also higher in MERKO than WT 
mice. As mentioned earlier, both ectopic deposition of lipid intermediates and skeletal 
muscle inflammation are implicated in the etiology of lipid-induced insulin resistance 
(Kitessa & Abeywardena, 2016; Wu & Ballantyne, 2017). Consistent with this notion, 
MERKO mice exhibit reduced whole body insulin sensitivity. Data from the 
hyperinsulinemic-euglycemic clamp have revealed that insulin-stimulated glucose 
disposal rate is reduced by 45% in MERKO mice, indicating significant skeletal muscle 
insulin resistance. Ex vivo insulin-stimulated skeletal muscle glucose uptake is also 
lower by 55% in MERKO mice, along with lower protein content of skeletal muscle 
insulin signaling molecules, p85 subunit of IRS-1 and p-Akt, than WT mice. Currently, 
no studies on skeletal muscle-specific ERα in male mice have been conducted; 
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therefore, whether ERα function in skeletal muscle is sexually dimorphic remains to be 
determined.  
 
Overall, these studies suggest that from a metabolic perspective, the ERα 
site of action for maintaining both glucose and lipid homeostasis is in the skeletal 
muscle. However, compensatory mechanisms that occur during development may 
have substantially contributed to the phenotype of adult skeletal muscle-specific ERαKO 
mice, and as a result, primary and secondary effects of the loss of skeletal muscle ERα 
cannot be differentiated. Finally, considering that most women are born with normal 
estrogen function, the existing global and skeletal muscle-specific ERαKO mouse 
models do not truly represent women since these ERαKO mice lack the estrogen-ERα 
interaction since development. Therefore, our current understanding of the importance 
of ERα to skeletal muscle is limited by the current state of the animal models. 
 
Regulation of Mitochondrial Function by Estrogens 
 
The following section will discuss how estrogens are thought to influence aspects 
of mitochondrial function, including mitochondrial respiration, reactive oxygen species 
(ROS) emission, and mitochondrial fusion-fission dynamics, by direct and indirect 
regulation of mitochondrial-encoded gene transcription.   
 
Estrogens indirectly regulate mitochondrial-encoded gene transcription 
(Jin-qiang Qiang Chen, Brown, & Russo, 2009; Klinge, 2017). For example, COX-7RP 
is a nuclear-encoded mitochondrial gene that contains an ERE, which has been 
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documented to increase with estradiol treatment (Watanabe et al., 1998). Studies in 
MCF-7 breast cancer cells and H1793 lung adenocarcinoma cells have also shown that 
ERα mediates the estradiol-induced increase in the nuclear-encoded nuclear respiratory 
factor-1 (NRF-1), which plays a major role in mitochondrial biogenesis (Mattingly et al., 
2008). ChIP assays in MCF-7 cells have demonstrated the interaction between ERα 
and NRF-1, which contains an imperfect ERE (Mattingly et al., 2008). Furthermore, a 
previous study has shown that silencing ERα by siRNA inhibits the estradiol-induced 
increase in NRF-1, but silencing ERβ has no effect (Mattingly et al., 2008). NRF-1 
activation promotes mitochondrial biogenesis by activating Transcription Factor A, 
Mitochondrial (TFAM), which is a major inducer of mtDNA gene transcription (Scarpulla, 
2012). Indeed, the estradiol-induced upregulation of NRF-1 increases TFAM, and 
concurrently increases the expression of mitochondrial-encoded cytochrome c oxidase 
subunit-1 (COX-1) and NADH dehydrogenase subunit-1 in MCF-7 cells (Mattingly et al., 
2008). Other studies have also demonstrated that estradiol, via NRF-1, regulates the 
following nuclear DNA-encoded genes: Complex I subunit NDUSF-8, succinate 
dehydrogenase complex subunit B, cytochrome C, COX-4, COX-5a, COX-5b, COX-6b, 
COX-6c, COX-7b, COX-7c, COX-8, COX17p, F0 ATP synthase subunits d-g, and F1 
ATP synthase γ (J. Chen, Cammarata, Baines, & Yager, 2009). NRF-1 and TFAM 
expression are also increased in skeletal muscle of OVX rats (Capllonch-Amer et al., 
2014), and in hearts, mammary gland, and uterus of OVX mice (Y. Chen et al., 2015; 
Ivanova, Radde, Son, Mehta, & Klinge, 2013) after short (e.g. 4 weeks) and long term 
(e.g. 3 months) estradiol treatment.  
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Estrogen-ER signaling also appears to regulate mitochondrial function by 
direct mtDNA-encoded gene transcription of certain Complex I-V subunits in 
electron transport system (ETS) (Jin-qiang Qiang Chen et al., 2009; Jin Qiang Chen, 
Yager, & Russo, 2005). MtDNA has been previously shown to contain ERE-like 
sequences, which coincides with an estradiol-induced increase in ETS activity (J. Chen 
et al., 2009). Furthermore, electrophoresis mobility shift and surface plasmon resonance 
assays demonstrate that ERα and ERβ can bind to mtDNA ERE-like sequences in 
MCF-7 cells, and that their binding affinity increases with increasing dosage and longer 
estrogen exposure (Jin Q. Chen, Eshete, Alworth, & Yager, 2004). Some studies have 
also reported that ERα and ERβ localize in the mitochondria of different tissues and cell 
types such as human heart, human fetal brown adipose tissue, rat hippocampal 
neurons, MCF-7 cells, HepG2 cells, providing added support for the direct regulation of 
mtDNA-encoded genes (Klinge, 2017; Pedram, Razandi, Wallace, & Levin, 2006; Yager 
& Chen, 2007). Notably, the concept that ERs localize in the mitochondria remains to be 
controversial or appears to be tissue-dependent. Since most studies have used 
immunoblot and immunohistochemistry techniques (Klinge, 2017), some have argued 
that such data are not reliable since ER antibodies have been previously shown to yield 
non-specific results [141]. Data from mass spectrometry studies are also mixed (Klinge, 
2017). Only one study has detected ERβ in human heart mitochondria by MALDI-TOF 
(Yang et al., 2004). However, other mass spectrometry studies on mitochondria in over 
14 different mouse tissues have documented that ERs do not localize in the 
mitochondria (Klinge, 2017). Furthermore, a recent study on OVX and skeletal muscle-
specific ERαKO mice has demonstrated that estradiol directly incorporates into the 
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mitochondrial membrane, in the absence of ERα, which enhances the fluidity of the 
membrane and in turn, improves Complex I- and Complex III-specific activities and 
reduces H2O2 emission potential (Torres et al., 2018). 
Direct and indirect regulation of mitochondrial proteins by estradiol can 
affect mitochondrial respiratory capacity. Decreased circulating estrogens by 
ovariectomy results in reduced mitochondrial respiratory capacity, and estrogen 
treatment improves it. For instance, isolated heart mitochondria of young adult OVX rats 
display lower protein content and enzyme activities of Complex-I, Complex-IV, pyruvate 
dehydrogenase, and 2-oxoglutarate dehydrogenase at 2 months post-surgery (Pavón et 
al., 2017). At 3 months post-surgery, OVX rats exhibit lower maximal respiratory 
capacity in the presence of glutamate/malate compared to controls (Pavón et al., 2017). 
Another study has also demonstrated that estradiol treatment for 4 weeks results in 
higher activity of ETS enzymes important for ATP production, citrate synthase, and 
COX-4, in cerebral blood vessels of young adult OVX rats (Stirone, Duckles, Krause, & 
Procaccio, 2005). In skeletal muscle, respiratory capacity of permeabilized muscle 
fibers at 8 weeks post-ovariectomy is similar between young adult OVX rats and age-
matched sham-operated mice when normalized to citrate synthase activity, but is lower 
when normalized to fiber weight (Cavalcanti-de-Albuquerque et al., 2014). The authors 
of this study have suggested that muscle fibers of these OVX rats have lower 
mitochondrial content (Cavalcanti-de-Albuquerque et al., 2014). In mice, ovariectomy 
leads to a reduction in muscle fiber respiratory capacity by ~25% in the presence of 
glutamate/malate and ~45% in the presence of fatty acids in as early as 2 weeks post-
surgery (OVX-2w), which decreases even more at 4 weeks post-ovariectomy (Torres et 
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al., 2018). Conversely, respiratory capacity (in the presence of pyruvate/malate and 
glutamate/malate) of OVX-2w mice treated with estradiol for 2 weeks is similar to the 
rates observed in ovary-intact mice, which is accordingly higher than untreated OVX 
mice (Torres et al., 2018). The role of estradiol in maintaining respiratory capacity 
appears to be mediated by ERα in skeletal muscle. This has been demonstrated in a 
study on C2C12 myotubes transduced with lentiviral ERαshRNA, which exhibit a 40-
50% decrease in basal and maximal respiratory capacity, a ~50% decrease in ATP 
synthesis, and a ~50% lower palmitate oxidation rate (Ribas et al., 2016). However, no 
direct measures have been made in mature skeletal muscle with intact cellular and 
mitochondrial architecture. Furthermore, as mentioned earlier, estradiol can localize to 
the mitochondrial membrane and improve membrane fluidity, which in turn increases 
respiratory capacity of skeletal muscle mitochondria, independent of ERα (Torres et al., 
2018). Thus, whether skeletal muscle-specific ERα mediates the reductions in 
respiratory capacity ex vivo or in vivo remains to be determined.  
Estradiol also regulates mitochondrial reactive oxygen species (ROS) 
exposure. In models of reduced estrogen action, the cellular antioxidant responses are 
altered, resulting in increased emitting potential of hydrogen peroxide (H2O2), a major 
form of ROS in the mitochondria (Wong, Dighe, Mezera, Monternier, & Brand, 2017). 
For example, our lab has shown that H2O2 emission potential is higher in isolated liver 
mitochondria of OVX mice than sham-operated mice, which is attributed to a reduction 
in protein content of glutathione peroxidase-1, a major antioxidant enzyme in liver 
mitochondria of OVX mice (Valencia et al., 2016). Another study has also demonstrated 
that cerebral blood vessels of OVX rats treated with estradiol for 4 weeks exhibit lower 
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H2O2 emission potential and concomitantly, higher MnSOD protein content compared to 
untreated OVX rats (Stirone et al., 2005). Young adult OVX rats also display greater 
hydrogen peroxide (H2O2) emission potential in skeletal muscle fibers than sham-
operated rats at 4 weeks post-ovariectomy (Capllonch-Amer et al., 2014). Similarly, a 
recent study has reported that permeabilized skeletal muscle fibers of OVX mice exhibit 
higher H2O2 emission potential than SHAM mice in as early as 2 weeks post-surgery, 
accompanied by a reduction in the capacity of glutathione to reduce ROS levels, as 
indicated by a lower reduced-to-oxidized glutathione (GSH/GSSG) ratio (Pavón et al., 
2017). Conversely, permeabilized muscle fibers of OVX mice treated with estradiol for 2 
weeks display lower H2O2 emission potential (in the presence of pyruvate) than 
untreated OVX mice (Pavón et al., 2017). Overall, these studies support the notion that 
estradiol plays a role in regulating redox homeostasis. One study has reported that ERα 
function is critical for the regulation of ROS levels in skeletal muscle, such that muscle-
specific ERαKO (MERKO) mice exhibit greater protein carbonylation in skeletal muscle 
(a marker of elevated mitochondrial and non-mitochondrial ROS) and lower glutathione 
peroxidase-3 (also a member of the glutathione antioxidant system) (Ribas et al., 2016). 
Increased ROS levels are similarly observed in C2C12 myocytes transduced with 
lentiviral ERαshRNA (Ribas et al., 2016). However, no study has directly measured 
whether ERα functions to regulate mitochondrial H2O2 emission in mature skeletal 
muscle with intact mitochondrial architecture. 
Mitochondrial function is also influenced by estradiol’s regulation of 
mitochondrial fusion and fission via both ER-dependent and independent 
mechanisms. A previous study has demonstrated that estradiol increases the 
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expression of fusion proteins mitofusin-1 and -2 (MFN-1 and MFN-2) in MCF-7, MDA-
MB-231, and T47D cancer cells (Sastre-Serra, Nadal-Serrano, Pons, Roca, & Oliver, 
2013). Fusion protein optic atrophy-1 homolog (OPA-1) expression is higher in 
estradiol-treated MCF-7 (ER+) cells, but not in MDA-MB-231 (ER-) cells, indicating that 
estradiol modulates the expression of OPA-1 in an ER-dependent manner (Sastre-Serra 
et al., 2013). On the other hand, dynamin-related protein-1 (DRP-1) is higher in 
estradiol-treated MDA-MB-231 cells, but not in MCF-7 cells, indicating the involvement 
of an ER-independent mechanism (Sastre-Serra et al., 2013). Estradiol also reduces 
fission-1 homolog (FIS-1) expression in MCF-7 cells, but not MDA-MB-231 (Sastre-
Serra et al., 2013). Alterations in mitochondrial fusion and fission dynamics may alter 
mitochondrial function. For instance, a previous study has reported that young adult, 
OVX rats exhibit lower MFN1, MFN2, and DRP1 protein content in skeletal muscle than 
SHAM rats, which coincide with lower mitochondrial respiratory capacity compared to 
control rats (Capllonch-Amer et al., 2014). However, skeletal muscle-specific ERα loss 
may not be the mediator of altered mitochondrial fusion that occurs with ovariectomy. A 
recent study has observed that conventional skeletal muscle-specific ERαKO mice 
(MERKO) exhibit impaired mitochondrial fission, as indicated by hyper-fused 
intermyofibrillar mitochondria, less dense subsarcolemmal mitochondria, ~50% lower 






The current state of the literature points to skeletal muscle-specific ERα 
action as a critical role in regulator of glucose dynamics, lipid homeostasis, and 
mitochondrial function in skeletal muscle. However, the available data on muscle-
specific ERα function is limited, and is likely confounded by developmental effects due 
to losing ERα at conception. The inducible tissue-specific conditional knockout 
overcomes the aforementioned limitations, and is one of the most powerful and 
innovative techniques to date (J. J. McCarthy, Srikuea, Kirby, Peterson, & Esser, 2012). 
This tool allows mice to mature with normal estrogen-ERα function until genetic ablation 
of ERα is desired. The current study aimed to investigate the role of skeletal muscle 
ERα in preventing metabolic dysfunction by utilizing an inducible skeletal muscle-
specific ERα knockout mouse model so that the function of ERα can be precisely 
defined without the confounding factors of development. 
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Estrogen receptor-α (ERα) belongs to the nuclear receptor family and is thought 
to play a significant role in the regulation of skeletal muscle glucose and lipid 
homeostasis. However, current skeletal muscle-specific ERα loss-of-function 
approaches have likely affected developmental mechanisms, making it difficult to 
assess the effect of ERα loss in adult mice. Here, we determined whether skeletal 
muscle ERα is critical for maintaining metabolic function in adult mice by utilizing a 
novel inducible skeletal muscle-specific ERα knockout mouse model (ERαKOism). We 
hypothesized that the loss of ERα function in adult skeletal muscle increases the 
susceptibility to high fat diet-induced metabolic dysfunction. At 20-22 weeks of age, 
female and male wild-type (WT) and ERαKOism mice were given either a control (low 
fat) diet (CD, 10% kcal fat) or high fat diet (HFD, 45% kcal fat) for 12 weeks. Body 
composition and glucose tolerance were assessed after acute (1 week) and chronic (11 
weeks) HFD treatment. Whole body metabolism was measured at baseline, during the 
switch to a HFD, and on the 11th week of HFD treatment by indirect calorimetry. Ex vivo 
skeletal muscle glucose uptake, indices of mitochondrial function, and markers of 
inflammation in skeletal muscle were assessed after the 12-week HFD treatment. At 
baseline, body mass, fat mass, and lean mass were similar among the groups, for both 
females and males. The change in body mass and fat mass over the course of the 
study were similar between WT-CD and ERαKOism-CD mice, for both females and 
males. Chronic HFD treatment increased total body fat mass with no significant 
differences between genotype, for both females and males. After chronic HFD 
treatment, energy expenditure of male ERαKOism mice was minimally higher than WT 
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mice, regardless of diet, despite no significant differences in spontaneous cage activity. 
Analysis of glucose dynamics revealed that female ERαKOism-HFD mice were more 
glucose intolerant than WT-HFD mice. Ex vivo basal and insulin-stimulated skeletal 
muscle glucose uptake was similar between WT and ERαKOism mice, and chronic HFD 
treatment led to a reduction in glucose uptake, regardless of genotype. Interestingly, 
female ERαKOism have lower skeletal muscle GLUT4 protein content and increased 
expression of pro-inflammatory markers in skeletal muscle compared to WT mice, 
regardless of diet. Finally, permeabilized muscle fibers of WT and ERαKOism mice, 
regardless of diet, exhibited similar mitochondrial respiratory capacity, OXPHOS 
efficiency, and H2O2 emission potential for both females and males. Chronic HFD 
treatment did not negatively affect skeletal muscle mitochondrial function of female and 
male ERαKOism mice. To determine whether our findings on mitochondrial function 
similarly occur in human skeletal muscle, we silenced ERα in cultured human myotubes 
using an adenovirus-driven ERαshRNA (ERαKD). ERαKD myotubes sourced from 
healthy women displayed a minimal reduction in ATP production rate. ERαKD myotubes 
from obese-insulin resistant women exhibited slightly reduced basal O2 consumption 
and ATP production rates. Overall, our data suggest that skeletal muscle ERα is critical 
for preventing glucose intolerance in females on a chronic HFD and regulating skeletal 
muscle inflammation. Furthermore, induced loss of ERα in adult skeletal muscle does 






Ovarian senescence (Gold, 2011), bilateral oophorectomy (Hendrix, 2005), 
aromatase deficiency (M. Jones et al., 2006), and estrogen receptor polymorphisms 
(Smith et al., 1994) lead to a significant reduction in estrogen action, and all these 
conditions are associated with the increased risk of developing obesity and peripheral 
insulin resistance, which can progress to overt Type 2 Diabetes (Carr, 2003; Lo et al., 
2006; Park et al., 2003; Pu et al., 2017). Conversely, administering pharmacological 
levels of estrogen is an effective approach for decreasing adiposity and improving 
peripheral insulin sensitivity (Ahtiainen et al., 2012; A. M. McCarthy et al., 2013; 
Salpeter et al., 2006). However, observational studies in the 1970s have documented 
that the use of conjugated equine estrogen (CEE), the most popular form estrogen 
therapy at that time, increases the risk of endometrial cancer (Ziel & Finkle, 1975). 
Moreover, the largest randomized control trial study on postmenopausal hormone 
therapy, called the Women’s Health Initiative, has found statistical associations between 
estrogen therapies (CEE and CEE + medroxyprogesterone acetate) and increased 
incidence of breast cancer, coronary heart disease, stroke, and pulmonary embolism 
(G. Anderson et al., 2004; Rossouw et al., 2002). Since then, the urgency to improve 
our therapeutic strategies has required a better understanding of estrogen-sensitive 
mechanisms across all tissues. 
Estrogen action at each individual tissue is predominantly mediated by tissue 
expression of each specific receptor (Couse et al., 1997) and estrogens’ affinity for the 
expressed receptor (Kuhl, 2005). Numerous studies on estrogen receptors may have 
revealed a potential new target for modulating metabolism (R. P. a Barros & 
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Gustafsson, 2011; Hevener, Clegg, & Mauvais-Jarvis, 2015). Among the estrogen 
receptors that mediate estrogen signaling in cells, estrogen receptor-alpha (ERα) 
appears to play a key role in the regulation of glucose and lipid homeostasis. Global 
ERα knockout mice (ERαKO) exhibit excess visceral adiposity and insulin resistance 
(Bryzgalova et al., 2006; Heine et al., 2000; Ohlsson et al., 2000; Ribas et al., 2010), 
whereas global ERβKO mice have normal body mass, fat mass, and insulin sensitivity 
(Bryzgalova et al., 2006; Ohlsson et al., 2000). Additionally, the consensus on whether 
the G-protein coupled estrogen receptor is a true estrogen receptor remains to be 
determined (Levin, 2009a).  
Tissue-specific ERα loss-of-function models have allowed the dissection of 
primary versus secondary effects and the functions of ERα in regulating glucose and 
lipid metabolism at each specific tissue. For instance, induced knockdown of liver ERα 
by injection of adeno-associated virus-Cre (driven by the liver-specific thyroid binding 
globulin promoter) in 2-3 month old male ERα-floxed mice results in hepatic steatosis, 
along with a modest increase in fasting glucose that is attributed to decreased inhibition 
of gluconeogenic enzymes in the liver, glucose-6-phosphatase and 
phosphoenolpyruvate carboxykinase-1 (Qiu et al., 2017). However, conventional liver-
specific ERαKO mice with no liver ERα function since embryonic development display 
normal body mass, fat mass, glucose tolerance, and even after a 5-month high fat diet 
(Matic et al., 2013). The disparity between these findings from 2 different loss-of-
function approaches emphasize the importance of conducting more studies on ERα 
function without the confounding factors of development.  
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Skeletal muscle-specific ERα appears to play key roles in preventing metabolic 
dysfunction. Global ERαKO female mice exhibit ectopic deposition of triglycerides, 
diglycerides, and ceramides, reduced expression of fatty acid oxidation markers, as well 
as elevated expression of pro-inflammatory markers in skeletal muscle (Ribas et al., 
2010), all of which have been associated with the development insulin resistance 
(Befroy et al., 2007; Holland et al., 2007; Szendroedi et al., 2014; Wu & Ballantyne, 
2017). Indeed, a hyperinsulinemic-euglycemic clamp study has demonstrated that 
global ERαKO female mice display significantly decreased glucose disposal rate, 
indicating substantial skeletal muscle insulin resistance [207]. This is accompanied by 
impaired insulin signaling; although, GLUT4, the main glucose transporter in skeletal 
muscle, is not affected by the loss of ERα (Ribas et al., 2010). Other studies, however, 
have reported reduced GLUT4 protein content in skeletal muscle of global ERαKO mice 
(R. Barros et al., 2009, 2006). Thus far, only one study has investigated the role of 
skeletal muscle-specific ERα in the regulation of glucose and lipid homeostasis by 
utilizing conditional tissue-specific knockout mice, which have lost skeletal muscle-
specific ERα function during the embryonic stage of development (MERKO mice) (Ribas 
et al., 2016). Female MERKO mice exhibit increased visceral adiposity and reduced 
insulin sensitivity at 7 months of age (Ribas et al., 2016). Skeletal muscle of female 
MERKO mice display significant accumulation of lipid intermediates, inflammation, and 
insulin resistance, similar to the metabolic phenotype to global ERαKO mice (Ribas et 
al., 2016). These findings suggest that skeletal muscle-specific ERα may be critical for 
preventing significant increases in adiposity and inflammation as well as maintaining 
insulin sensitivity in adult mice. However, no studies have investigated the in vivo role of 
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skeletal muscle ERα in regulating metabolic homeostasis, without the confounding 
factors associated with development. 
Estrogens also regulate mitochondrial function, which appears to be mediated by 
ERα. Indeed, our lab (Valencia et al., 2016) and others (Cavalcanti-de-Albuquerque et 
al., 2014; Pavón et al., 2017; Stirone et al., 2005; Torres et al., 2018) have previously 
demonstrated that reduced estrogen action by ovariectomy results in increased 
mitochondrial reactive oxygen species (ROS), particularly H2O2 emission potential 
and/or reduced mitochondrial respiratory capacity in multiple tissues, including skeletal 
muscle (Torres et al., 2018). 17β-estradiol treatment has also been recently reported to 
improve these aspects of mitochondrial function in skeletal muscle fibers of 
ovariectomized mice (Torres et al., 2018). Recent evidence suggest that ERα is 
important for maintaining mitochondrial health (Ribas et al., 2016). Female MERKO 
mice exhibit mitochondrial morphological abnormalities such as hyper-fused 
intermyofibrillar mitochondria and a reduction in the density of subsarcolemmal 
mitochondria (Ribas et al., 2016). Additionally, mitochondrial DNA (mtDNA) turnover is 
reduced, and protein carbonylation levels, a marker of increased ROS levels 
(mitochondrial and non-mitochondrial ROS), are significantly elevated in skeletal muscle 
of MERKO mice. In C2C12 myotubes, ERα knockdown by lentiviral-ERαshRNA is 
reported to drastically lower basal and ADP-supported maximal O2 consumption, ATP 
production, and fatty acid oxidation rates by approximately 40-50% (Ribas et al., 2016). 
ERα has also been demonstrated to regulate mitochondrial DNA- and nuclear DNA-
encoded gene transcription of certain subunits of the electron transport system via 
direct and indirect mechanisms in other cell types such as breast cancer (MCF-7) cells 
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(Klinge, 2017). However, at this point, no direct functional measures have been made in 
adult skeletal muscle with intact mitochondrial architecture to assess whether skeletal 
muscle-specific ERα regulates mitochondrial respiratory capacity, oxidative 
phosphorylation efficiency, and mitochondrial-specific ROS emission. Since lipid-
induced insulin resistance has been linked to elevated mitochondrial H2O2 emission 
potential and reduced mitochondrial function that occur with chronic overnutrition (E. J. 
Anderson et al., 2009; Fisher-Wellman & Neufer, 2012), the role of skeletal muscle ERα 
in maintaining mitochondrial function may be critical for the regulation of glucose and 
lipid homeostasis. 
We sought to advance our understanding of skeletal muscle ERα function by 
generating a novel inducible skeletal muscle-specific ERα knockout (ERαKOism) mouse 
model, using the tamoxifen-inducible Cre-loxP system. In this study, skeletal muscle 
ERα function was ablated in adult mice after Cre activation at 10-12 weeks of age, 
which eliminated the confounding factors associated with ERα loss during development. 
The purpose of the study was to determine whether skeletal muscle-specific ERα is 
critical for maintaining metabolic homeostasis under acute and chronic conditions of 
nutrition overload. We hypothesized that induced ablation of skeletal muscle-specific 
ERα in female and male adult mice increases the susceptibility to high fat diet-induced 
metabolic dysfunction. The major finding of this study was that induced ablation of 
skeletal muscle ERα in female adult mice led to glucose intolerance after chronic HFD 
treatment, which may, in part, be due to increased expression of pro-inflammatory 
markers and reduced GLUT4 protein content in skeletal muscle. These findings were 
not due to alterations in adiposity or mitochondrial function. Altogether, our data suggest 
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that skeletal muscle ERα mediates the protective role of estrogens against HFD-
induced glucose intolerance in females by regulating skeletal muscle inflammation and 
preserving skeletal muscle GLUT4 levels.  
 
Methods 
Generation of Inducible Skeletal Muscle-Specific Estrogen Receptor-Alpha 
Knockout Mice 
To assess the in vivo role of ERα, specifically in skeletal muscle, we generated 
an inducible skeletal muscle-specific ERα knockout (ERαKOism) mouse model. 
ERαflox/flox mice, which carry ESR1 with exon 3 flanked by loxP sites (a kind gift from Dr. 
K. Korach, National Institute of Environmental Health Sciences), were crossed with the 
tamoxifen-inducible Cre transgenic line driven by the human α-skeletal actin promoter 
(HSA-MCM) (a kind gift from Dr. K. Esser, University of Kentucky College of Medicine). 
Mice were backcrossed 8-9 generations, with SNP analysis demonstrating >99% of 
genome from C57Bl/6N. To determine whether the offspring possessed ERαflox/flox and 
HSA-MCM, mice were genotyped by polymerase chain reaction (PCR) using the 
following primer sets: 1) ERαflox/flox F: 5’-GACTCGCTACTGTGCCGTGTGC-3’ and R: 5’-
CTTCCCTGGCATTACCACTTCTCCT-3’, and 2) HSA-MCM F: 5’-
GGCATGGTGGAGATCTTTGA-3’ and R: 5’-CGACCGGCAAACGGACAGAAGC-3’. In 
this model, Cre recombinase is only activated when tamoxifen binds to Mer (mutated 
estrogen receptor), and is not activated by endogenous estrogens. Adult female and 
male mice (10-12 wks of age) with ERαflox/flox x HSA-MCM were injected 
intraperitoneally with 2mg of tamoxifen (Sigma #T5648), once a day for 5 days, as 
previously described (Jackson et al., 2018), to induce recombination of flox sites on 
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exon 3. In parallel, genetically-identical mice (age- and gender-matched) were injected 
with the vehicle and served as the control or wild-type (WT) mice in this study. Mice 
were further aged for 10 weeks before any experiments and diet treatments were 
performed to ensure the washout of tamoxifen and that ERα protein was no longer 
detected in skeletal muscle. Successful recombination of ERα in skeletal muscle was 
assessed through PCR. DNA was extracted using the Puregene Tissue Kit (Qiagen). 
PCR was performed using the HotStarTaq Plus Master Mix Kit (Qiagen) along with the 
following primers: primer 1, 5’-TTGCCCGATAACAATAACAT-3’ and primer 2, 5’-
GGCATTACCACTTCTCCTGGGAGTCT-3’. Finally, in previous experiments, we found 
no evidence of Cre-toxicity. We also injected HSA-MCM with tamoxifen per the above 
protocol and found no effect on glucose dynamics or mitochondrial respiration 
measures with this approach (Jackson et al., 2018). 
 
Research Experimental Design 
For both females and males, mice were divided into 4 groups based on genotype 
and diet: 1) wild-type on control low fat diet (WT-CD), 2) wild-type on high fat diet (WT-
HFD), 3) ERαKOism on control (low fat) diet (ERαKOism-CD), and 4) ERαKOism on high 
fat diet (ERαKOism-HFD). All mice were given water and food ad libitum in a room on a 
12h light/dark cycle. WT and ERαKOism mice were first fed a CD for 1 week prior to the 
HFD. Mice were subsequently fed either a CD or HFD for 12 weeks. CD contained 10% 
fat, 70% carbohydrates, and 20% protein while HFD contained 45% fat, 35% 
carbohydrates, and 20% protein. All rodent diets were obtained from Research Diets, 
Inc., New Brunswick, NJ (CD: D12450Ki, HFD: D12451i). Whole body and skeletal 
muscle metabolic function were assessed after acute (1-week) and chronic (12-week) 
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exposure to the HFD. Mice were sacrificed at the end of the 12-week HFD treatment. All 
experiments were approved by the Institutional Review Committee of East Carolina 
University.  
Body Composition and Food Intake 
Body mass and food intake were recorded weekly, and data from baseline until 
the 11th week of HFD treatment were analyzed. Fat mass and lean mass were 
measured using the EchoMRITM-500 Body Composition Analyzer (EchoMRI, Houston, 
Tx) according to the manufacturer’s protocol. 
 
Indirect Gas Calorimetry 
O2 consumption (VO2), CO2 production (VCO2), energy expenditure (H), and 
spontaneous cage activity levels of mice were measured using the TSE LabMaster 
System (TSE Systems, Chesterfield, MO) according to the manufacturer’s protocol. 
Calorimetry data were normalized to lean body mass. Activity levels were based on the 
absolute number of times infrared sensors in the x, y, and z planes were disturbed. All 
data were presented as the average of at least two 12hr light and dark cycles. 
Measurements were conducted at baseline, during the acute switch from control to high 
fat diet, and at the 11th week of HFD treatment.  
 
Glucose Tolerance Test   
Glucose tolerance was measured at the end of the 1st week and end of the 11th 
week of HFD treatment. Mice were fasted for 12 hours. A glucose bolus of 2mg/kg of 
body mass was injected in the intraperitoneal (IP) region. A glucometer was used to 
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measure glucose from blood drawn at the tail vein at the 0, 30th, 60th, and 120th 
minute. 
 
Ex Vivo Skeletal Muscle Glucose Uptake 
Extensor digitorum longus and soleus muscles were dissected from 12hr-fasted 
mice and used to measure glucose uptake as previously described (McMillin, Schmidt, 
Kahn, & Witczak, 2017). Briefly, muscles were incubated in 37°C gassed (95%O2, 5% 
CO2) Krebs Ringer Bicarbonate (KRB) buffer supplemented with 2mM pyruvate for 60 
min, and stimulated in the absence or presence of insulin (600μU/ml) for 20 min. 
Muscles were transferred to vials containing 30°C KRB buffer supplemented with 
1.5μCi/ml [3H]-2-deoxyglucose, 1mM 2-deoxyglucose, 0.45μCi/ml [14C]-mannitol, 7mM 
mannitol, with and without insulin for 10 min, and frozen in liquid nitrogen. Muscles were 
solubilized in 1N NaOH at 80°C for 15 min, and neutralized with 1N HCl. Samples were 
vortexed and centrifuged at 10,000xg for 1 min, and aliquots were removed for 
scintillation counting of the [3H] and [14C] labels.  
 
Mitochondrial Respiration using High-Resolution Respirometry 
Permeabilized skeletal muscle fibers from red gastrocnemius were used to 
measure mitochondrial respiratory capacity as previously described (Fisher-Wellman et 
al., 2015; Lark et al., 2016). Briefly, muscles were placed in buffer X (7.23mM K2EGTA, 
2.77mM CaK2EGTA, 20mM imidazole, 20mM taurine, 5.7mM ATP, 14.3mM 
phosphocreatine, 6.56mM MgCl2, and 50mM MES (pH 7.1), and fibers were separated 
with the aid of a dissecting microscope. For permeabilization, fiber bundles were 
incubated in buffer X, supplemented with 40μg/ml saponin, for 30 min. Permeabilized 
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muscle fibers were washed in buffer Z (110mM K-MES, 35mM KCl, 1mM EGTA, 5mM 
K2HPO4, 3mM MgCl26H2O, 5mg/ml bovine serum albumin, pH 7.4) at 4°C for 15 min. 
Permeabilized fibers were placed in the OROBOROS O2K Oxygraph chambers 
(Oroboros Instruments) filled with buffer Z that was supplemented with creatine 
monohydrate (20mmol/L) and 12.5μM blebbistatin. To determine respiratory capacity 
using carbohydrate-derived substrates, O2 consumption rate (OCR) was measured after 
each sequential addition of the following: 4mM pyruvate/ 0.5mM malate/ 5mM 
glutamate, 2.5mM ADP, 5mM Succinate, 5µM cytochrome c, 10mM rotenone, 5µM 
antimycin A/ 2mM ascorbate, 0.5mM TMPD. To determine respiratory capacity using 
fatty acid substrates, OCR was measured after each sequential addition of the 
following: 18µM palmitoyl-carnitine/20µM palmitoyl-CoA/5mM l-carnitine, 0.5mM malate, 
1mM ADP, 500nM FCCP. Data were normalized to fiber dry weight. 
 
Direct Measurement of Mitochondrial Oxidative Phosphorylation (OXPHOS) 
Efficiency  
OXPHOS efficiency was measured in permeabilized muscle fibers via the 
simultaneous quantification of ATP production and O2 consumption (OCR) rates as 
previously described (Lark et al., 2016), with minor modification. Permeabilized fibers 
were placed in the OROBOROS O2K Oxygraph (Oroboros Instruments) filled with 
buffer Z that was supplemented with 0.01mM blebbistatin and 0.2mM Ap5A. OCR was 
simultaneously measured with ATP production rate by quantification of NADPH 
fluorescence (Excitation/Emission: 340/460nm; FluoroMax-3, Horiba Jobin Yvon, 
Edison, NJ) at 37°C. In this assay, ATP production was determined using an enzyme-
linked assay, where the ATP hydrolyzed in a hexokinase reaction and subsequent 
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NADPH production through the glucose-6-phosphate dehydrogenase reaction results in 
a 1:1 stoichiometry. OXPHOS flux in permeabilized fibers was measured in the 
presence of 0.5mM malate/5mM pyruvate/ glutamate /5mM succinate followed by ADP 
titration (20μM, 200μM, and 2000μM). Data were normalized to fiber dry weight. 
OXPHOS efficiency (ATP/O ratio) was calculated by dividing the ATP production rate by 
the rate of atomic oxygen consumed. Permeabilized muscle fibers were prepared as 
mentioned above.  
 
Mitochondrial H2O2 Emission Potential  
Mitochondrial H2O2 emission potential was measured fluorometrically (FluoroLog, 
Horiba Jobin Yvon, Edison, NJ) in permeabilized muscle fibers using the Amplex Ultra 
Red/horseradish peroxidase detection system as previously described (Fisher-Wellman 
et al., 2015). Briefly, fibers were placed in a cuvette containing 10μM Amplex Ultra Red, 
1mM EGTA, supplemented with 25U/ml superoxide dismutase to convert superoxide 
into H2O2 and 25μM blebbistatin to prevent contraction. H2O2 emission rate was 
measured under 3 substrate conditions: 1) 10mM succinate, 2) 37.5µM palmitoyl-
carnitine/20µM palmitoyl-coA/5mM l-carnitine, and 3) 1mM pyruvate/ 5mM l-carnitine. 
For each assay, H2O2 emission rate was also measured in the presence of 1μM 
auranofin (AF), a thioredoxin reductase inhibitor, and 100μM bis-chloroethylnitrosourea 




Muscle Contractile Force Measurements 
Extensor digitorum longus muscle (EDL) was dissected and used to assess 
parameters of contractile function using a force transducer (Aurora Scientific Inc.) as 
previously described (Spangenburg, Le Roith, Ward, & Bodine, 2008).  
 
Silencing ERα in Human Myotubes 
Primary human skeletal muscle cells (HSKMCs) were provided as a kind gift by 
Dr. K. Funai (East Carolina University, Department of Kinesiology). HSKMCs were from 
vastus lateralis muscle biopsies of healthy and obese-insulin resistant young adult 
women (18-24 yrs of age). HSKMCs were differentiated into myotubes using standard 
methods. Briefly, HSKMCs were grown in DMEM with 5mM glucose (#11885 Gibco), 
supplemented with 10% FBS, Lonza SkGM SingleQuot (#CC-4139, Lonza) without 
gentamicin and insulin, and 100mg/ml penicillin-streptomycin (Gibco). At 90% 
confluency, differentiation was induced using DMEM with 5mM glucose (#11885 Gibco), 
supplemented with 2% heat inactivated horse serum (#26050, Gibco), 0.3% bovine 
serum albumin (#A-9025, Sigma Aldrich), 0.05% fetuin (#F-3385, Sigma Aldrich) and 
100mg/ml penicillin-streptomycin (Gibco). On the first day of differentiation, human 
myotubes were transduced with either scrambled-shRNA (Ad-U6-shRNA-RFP) or RFP-
tagged ESR1shRNA adenovirus (Ad-RFP-U6-h-ESR1-shRNA) that targets the coding 
region of ERα, both purchased from Vector Biolabs. Polybrene (SCBT #SC-134220) 
was used to increase transduction efficiency. Adenovirus infection was confirmed by 
imaging myotubes using a fluorescence microscope (EVOS FL Auto Cell Imaging 
System). No differences in differentiation potential were observed (data not shown). In 
all experiments, cells at passage 4-5 were used. 
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Mitochondrial Respiration Measurement in Human Myotubes 
On the 5th day of differentiation, O2 consumption rate (OCR) was measured using 
the XF24 Extracellular Analyzer and XFe96 Extracellular Analyzers according to the 
manufacturer’s protocols. Briefly, 50,000 HSKMCs and 20,000 HSKMCs were seeded 
in 24- and 96-well plates, respectively. Wells were coated with 20μg/ml ECL cell 
attachment matrix (#08-110, EMD Millipore). Myotubes were incubated in XF Base 
Medium with 1mM pyruvate, 2mM glutamine, and 10mM glucose (pH 7.4) for 1 hr at 
37°C in a non-CO2 incubator. Then, cells were placed into the XF Analyzer at 37°C, and 
OCR was measured after each sequential addition of the following: 1μM oligomycin, 
1μM carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), and 0.5μM 
rotenone/ antimycin A. Results were normalized to the amount of protein in each well, 
which was quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific).  
 
Expression Analysis by Real-Time Quantitative PCR (QT-PCR) 
Total mRNA was extracted from gastrocnemius muscle of mice using TRIzol 
(Ambion) and from human myotubes using RNeasy Mini Kit (Qiagen). Complementary 
DNA was synthesized from mRNA using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to the manufacturer’s protocol. Using 
Quant Studio 3 (Applied Biosystems), the following Taqman Gene Expression Assays 
(Thermo Fisher Scientific) were used to quantify mRNA expression: human Esr1 
(Hs00174860_m1), murine Esr1 (Mm00433149_m1), murine Esr2 (Mm00599821_m1), 
murine Tnf (Mm03928990_m1), murine Il6 (Mm00446190_m1), murine Il1b 
(Mm00434228_m1), murine Cxcl2 (Mm 00436450_m1), murine Cxcl1 
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(Mm04207460_m1), murine Ccl2 (Mm 00441242_m1), murine Ccl3 (Mm00441259_g1), 
human 18S (Hs99999901_s1), murine 18S (Mm03928990_g1).  
 
Immunoblotting 
Western blotting was performed using standard methods. Proteins were 
extracted from tibialis anterior muscles and human myotubes with lysis buffer (.05% 
IGEPAL CA-630, 20mM Tris-HCl, 150mM NaCl, 1mM EDTA) supplemented with a 
protease inhibitor cocktail (Pierce Protease Inhibitor Mini Tablets – Thermo Fisher 
Scientific). Lysates were centrifuged at 800g for 15 min at 4°C. Proteins (20-80μg) were 
separated by SDS-PAGE then transferred to PVDF membranes. Blots were probed with 
the following primary antibodies: ERα (SCBT #MC-20, rabbit, 1:800), total OXPHOS 
Human WB Antibody Cocktail (Abcam #ab110411, mouse, 1:250), GLUT4 (Millipore 
Corp #07-1404, rabbit, 1:2000), hexokinase II (SCBT #SC-6521, rabbit, 1:1000), and 
glycogen synthase (Cell Signaling #3886, goat, 1:2000). Then, blots were incubated 
with the appropriate secondary antibodies: donkey anti-rabbit IgG-HRP (SCBT #SC-
2313, 1:2000), goat anti-rabbit IgG (H+L) HRP (Thermo Fisher Scientific #P131460, 
1:2000), donkey anti-goat IgG (H+L) HRP (Thermo Fisher Scientific #PA128664, 
1:5000), or goat anti-mouse IgG (H+L) HRP (Thermo Fisher Scientific, #62-6520, 
1:2000). Blots were developed using chemiluminescent substrate (Pierce™ ECL 
Western Blotting Substrate, Thermo Fisher Scientific and WesternTM Lighting Plus 





All data are presented as Mean ± SEM. Statistical analyses were performed 
using PASW Statistics 18, Chicago, IL statistical software. The 2-way ANOVA was used 
for comparisons between mice that were grouped based on genotype and diet. The 3-
way mixed ANOVA was used to determine group differences (genotype and diet) over 
time. Two-tailed Independent and Dependent Student’s t-tests were also used when 
appropriate. For all statistical tests, p < .05 was considered significant. In cases where 
simple 2-way interactions were determined, the Bonferroni adjustment method was 
used, thus the statistically significant p-value was adjusted for the family of 
comparisons, dividing p < .05 by the number of comparisons made (i.e. two simple 2-
way interactions: .05 ÷ 2 = .025). 
 
Results 
Generation of Inducible Skeletal Muscle-Specific Estrogen Receptor-Alpha 
Knockout Mice 
Exon 3 of the gene that codes for ERα (ESR1) was genetically deleted in the 
skeletal muscle of adult (10-12 week old) mice using a tissue-specific tamoxifen 
inducible Cre-LoxP-based approach; thereby, ablating ERα function only in skeletal 
muscle (Fig. 1A). Recombination of ESR1 was not detected in skeletal muscle of 
vehicle-treated ERαflox/flox x HSA-MCM (WT) mice (Fig. 1B-C). Recombination of ESR1 
was detected in skeletal muscle of tamoxifen-treated ERαflox/flox x HSA-MCM (ERαKOism) 
mice, which was not detected in other organs (Fig. 1C). QT-PCR and western blot 
analyses confirmed that Esr1 mRNA and ERα protein were significantly reduced in 
skeletal muscle of tamoxifen-treated, but not in vehicle-treated female and male 
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ERαflox/flox x HSA-MCM mice (Fig. 1D-F). Chronic high fat diet (HFD)-fed female 
ERαKOism mice exhibited greater Esr1 mRNA expression than female ERαKOism mice 
on control (low fat) diet (CD) (Fig. 1D). In males, WT-HFD mice displayed lower Esr1 
expression than WT-CD mice (Fig. 1E). Although estrogen receptor beta (Esr2) mRNA 
expression was greater in female ERαKOism than WT mice, regardless of diet (Fig. 1D), 
Esr2 expression was several thousand fold lower than Esr1 expression in 
gastrocnemius of mice (Fig. 1D-E). Esr2 expression was lower in gastrocnemius of 
male WT-HFD, ERαKOism-CD, ERαKOism-HFD than WT-CD mice (Fig. 1E). Esr1 
expression was also detected across multiple skeletal muscle tissues and other organs 
of WT mice, was highest in murine uterus, and was several thousand lower in C2C12 
myotubes compared to murine skeletal muscle (Supplementary Fig. 1). Finally, we 
found that the three major isoforms of ERα are localized to the nucleus in skeletal 
muscle (Supplementary Fig. 2). 
 
Body Composition of ERαKOism Mice after Acute and Chronic HFD 
At baseline, all groups exhibited similar body mass, fat mass, and lean mass for 
both females (Fig. 2A, C, E) and males (Fig. 2I, K, M). The change in body composition 
over time was greater in HFD-fed than CD-fed mice, but no significant differences 
between genotype were observed, for both females (Fig. 2B, D, F) and males (Fig. 2J, 
L, N). In female mice, body mass and fat mass were similar among groups after acute 
(1-week) exposure to HFD, and greater in HFD fed mice, regardless of genotype, after 
chronic (11-week) exposure to HFD (Fig. 2A, C). Lean mass of female ERαKOism mice, 
regardless of diet, was statistically lower than WT mice after acute HFD treatment, but 
was not significantly different among groups after chronic HFD treatment (Fig. 2E). In 
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male mice, body mass, fat mass, and lean mass were similar among the groups after 
acute HFD, and were greater in HFD-fed male mice after chronic HFD, regardless of 
genotype (Fig. 2I, K, M). Food intake was similar among the groups for both sexes over 
the course of the study (Fig. 2H, P). Liver and heart mass were not affected by diet or 
genotype (Table 1). In females, gonadal fat mass was greater in HFD-fed mice, 
regardless of genotype (Table 1). On the other hand, male ERαKOism-HFD mice 
exhibited lower gonadal fat mass than WT-HFD mice (Table 1).  
 
Whole Body Metabolic Assessment during Acute and Chronic HFD 
Indirect gas calorimetry revealed that female ERαKOism was similar to WT, 
regardless of diet. O2 consumption (VO2), CO2 production (VCO2), respiratory exchange 
ratio (RER), energy expenditure (H), and activity counts were not significantly different 
among groups at baseline (Fig. 3A, 4A). The acute switch from CD to HFD lowered 
VCO2 during the dark cycle in female WT- and ERαKOism-HFD mice, which resulted in 
decreased RER (Fig. 3B). There were no significant differences in energy expenditure 
and activity counts among the groups during the switch from CD to HFD (Fig. 4B). 
Female HFD-fed mice, regardless of genotype, exhibited lower RER during the light and 
dark cycles after chronic HFD treatment, than CD-fed mice (Fig. 3C). Female HFD-fed 
mice, regardless of genotype, also exhibited greater energy expenditure and lower 
spontaneous cage activity after chronic HFD treatment than CD-fed mice, especially 
during the dark cycle (Fig. 4C).  
Male ERαKOism mice, regardless of diet, exhibited higher baseline RER than WT 
mice during the dark cycle (Fig. 5A). There were no significant differences in baseline 
energy expenditure and activity counts among the male groups (Fig. 6A). The switch 
73 
 
from CD to HFD lowered RER in male HFD-fed mice, regardless of genotype (Fig. 5B). 
Notably, RER was similar between male WT-CD and ERαKOism-CD mice during the diet 
switch, suggesting our finding at baseline was only a transient effect (Fig. 5B). Energy 
expenditure and activity counts were not affected in male mice during the diet switch 
(Fig. 6B). Chronic HFD feeding reduced RER of male HFD-fed mice, regardless of 
genotype (Fig. 5C). Male ERαKOism mice, regardless of diet, exhibited minimally higher 
VO2, VCO2, and energy expenditure than the WT, especially during the dark cycle, after 
chronic HFD treatment (Fig. 5C, 6C). However, there were no statistical differences in 
spontaneous cage activity among the male groups (Fig. 6C). 
 
Glucose Dynamics after Acute and Chronic HFD 
The impact of skeletal muscle ERα ablation on glucose tolerance was assessed. 
Glucose tolerance was significantly different between CD- and HFD-fed female mice 
after acute exposure to a HFD, but no significant differences between genotype were 
observed (Fig. 7A). Interestingly, female ERαKOism-HFD exhibited greater glucose 
intolerance than WT-HFD after chronic exposure to a HFD (Fig. 7B). In male mice, the 
acute and chronic HFD treatments resulted in glucose intolerance in WT-HFD and 
ERαKOism-HFD, but there were no significant differences between genotype (Fig. 7A-B).  
Skeletal muscle glucose uptake was assessed ex vivo, using [3H]-2-deoxy-D-
glucose, after chronic HFD treatment. Basal and insulin-stimulated glucose uptake in 
both extensor digitorum longus (EDL) and soleus muscles were not impaired in female 
ERαKOism-CD and ERαKOism-HFD mice; although, muscle glucose uptake was lower in 
HFD-fed mice, regardless of genotype (Fig. 7C-D). After chronic HFD treatment, 
skeletal muscle of female ERαKOism exhibited lower GLUT4 protein content compared 
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to WT mice, regardless of diet (Fig. 7E). There were no significant differences in GLUT4 
protein content between male WT and ERαKOism (Fig. 7E). Hexokinase and glycogen 
synthase protein content were similar among groups, for both females and males (Fig. 
7F-G).  
 
Skeletal Muscle Inflammation after Chronic HFD 
Skeletal muscle mRNA expression of majority of the pro-inflammatory cytokines 
and chemokines that we measured were higher in female ERαKOism than WT mice, 
regardless of diet (Fig. 8). Specifically, tumor necrosis factor (TNF, also known as 
TNFα), interleukin-6 (IL6), chemokine (C-X-C motif) ligand-1  (CXCL1, also known as 
growth-regulated oncogene α, GROα), chemokine (C-C motif) ligand-3 (CCL3, also 
known as macrophage inflammatory protein-1-alpha, MIP-1-alpha), and chemokine (C-
C motif) ligand-2 (CCL2, also known as monocyte chemoattractant protein-1, MCP-1) 
were significantly greater in female ERαKOism than WT mice, regardless of diet (Figure 
8). Interleukin-1β (IL1B) expression was higher in female HFD-fed mice, regardless of 
genotype. Chemokine (C-X-C motif) ligand 2 (CXCL2, also called macrophage 
inflammatory protein 2-alpha, MIP2-alpha) expression was not significantly different 
among the groups.  
 
Functional Assessment of Skeletal Muscle Mitochondria In Situ after Chronic HFD 
Given that ERα is thought to play a prominent role in regulating mitochondrial 
function, we tested whether mitochondrial respiration in permeabilized skeletal muscle 
fibers was also affected by the induced in vivo ablation of skeletal muscle ERα. 
Mitochondrial respiratory capacity in the presence of pyruvate/malate/glutamate was not 
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reduced in permeabilized fibers of female and male ERαKOism mice, regardless of diet 
(Fig. 9A,C). In female mice, an increase in complex IV-supported respiration was 
observed in fibers of WT-HFD compared to WT-CD mice (Fig. 9A). In male mice, 
complex I-supported state 4 respiration was higher in HFD-fed than CD-fed mice, but 
there were no significant differences between genotype (Fig. 9C). Fatty acid-supported 
respiratory capacity (in the presence of palmitoyl-carnitine/palmitoyl-coA) was similar 
among the female groups (Fig. 9B). In male mice, fatty acid-supported state 4 
respiration was statistically greater in the HFD-fed than CD-fed groups, but there were 
no significant differences between genotype (Fig. 9D). Maximal ADP-supported 
respiration in the presence of fatty acid substrates was also higher in fibers of WT-HFD 
than WT-CD male mice (Fig. 9D). Nonetheless, the data suggest that mitochondrial 
respiratory capacity is not affected by the induced ablation of skeletal muscle ERα nor 
was it decreased after 12 weeks of high fat diet treatment. The rates of ATP production 
(JATP) and O2 consumption (JO2) were simultaneously measured to determine 
OXPHOS efficiency (defined as the molar amount of ATP produced per mole of atomic 
oxygen consumed, thus the ATP/O ratio) in skeletal muscle of ERαKOism mice. JATP, 
JO2, as well as ATP/O ratio in permeabilized fibers were not significantly different 
among the female groups (Fig. 10A-C). Permeabilized fibers of male HFD-fed mice, 
regardless of genotype, exhibited higher JATP in the presence of 200μM ADP as well 
as higher JO2 in the presence of 20μM ADP and 200μM ADP than CD-fed mice (Fig. 
10D-E). ATP/O ratio was not significantly different between WT and ERαKOism male 
mice, regardless of diet (Fig. 10F). In line with our findings on mitochondrial ATP 
production and OXPHOS efficiency in situ, contractile force and fatigue susceptibility 
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were not affected in female and male ERαKOism mice, regardless of diet 
(Supplementary Fig. 3). Furthermore, permeabilized fibers of female and male 
ERαKOism mice did not exhibit any significant differences in H2O2 emitting potential in 
the presence of succinate (Fig. 11A,D), palmitoyl-carnitine/palmitoyl-coA (Fig. 11B,E), 
or pyruvate/carnitine (Fig. 11C,F) compared to their WT counterparts, regardless of diet. 
For both sexes, JH2O2 increased in the presence of AF/BCNU in all substrate 
conditions; however, there were no significant differences in AF/BCNU response among 
the groups (Fig. 11A-F).  
 
Mitochondrial Respiration in Human Myotubes with Reduced ERα Function 
In an attempt to reconcile our investigation on the role of skeletal muscle ERα in 
mitochondrial function with a previous publication (Ribas et al., 2016), we measured 
mitochondrial respiration in human myotubes with significantly reduced ERα. Myotubes 
were cultured from primary human skeletal muscle cells isolated from muscle biopsies 
of female healthy and obese-insulin resistant (OIR) young adult women. Healthy women 
exhibited lower body weight, body mass index, fasting insulin and glucose levels, 
HOMA-IR, and higher maximal O2 consumption (VO2max) compared to OIR women 
(Table 2). Myotubes were transduced with an adenovirus expressing RFP-tagged 
ERαshRNA (ERαKD). Control myotubes expressed scrambled shRNA (Scrmbl). 
Transduction efficiency was similar between Scrmbl and ERαshRNA myotubes (Fig. 
12A). QT-PCR revealed that Esr1 (ERα) mRNA expression was significantly reduced in 
ERαKD myotubes compared to the Scrmbl condition (Fig. 12B). Mitochondrial 
respiration was not significantly different between the healthy- and OIR-Scrmbl 
myotubes (Fig. 12C). In myotubes from healthy subjects, ATP production rate was 
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minimally reduced by 16% in the ERαKD group compared to the Scrmbl group (Fig. 
12D). ERαKD myotubes from OIR subjects also exhibited statistically lower ATP 
production rate (~18%) in addition to the slightly lower basal O2 consumption rate 
(~16%) compared to the Scrmbl condition (Fig. 12E). These results were not due to 
alterations in protein content of the electron transport system complexes (Fig. 12F). No 
significant differences in uncoupled oxygen consumption rate were found between 
control and ERαKD myotubes from either healthy or obese groups (Fig. 12D-E). 
 
Discussion 
ERα is expressed in multiple tissues, and emerging evidence suggest that 
skeletal muscle-specific ERα has important roles in maintaining metabolic homeostasis 
(Ribas et al., 2010, 2016). However, available data from global (R. Barros et al., 2009, 
2006; Ribas et al., 2010) and conventional skeletal muscle-specific ERα knockout 
models (Ribas et al., 2016) may be confounded by factors associated with the loss of 
ERα during development. To overcome this limitation, we generated an inducible 
skeletal muscle-specific ERα knockout mouse. Our results confirmed that induced 
ablation of skeletal muscle-specific ERα increased the susceptibility to develop glucose 
intolerance in adult female mice on chronic HFD treatment. Skeletal muscle GLUT4 
protein content, the major glucose transporter in skeletal muscle, was lower in female 
ERαKOism than WT mice, regardless of diet. We observed sex differences in glucose 
tolerance and skeletal muscle GLUT4 protein expression as well. Glucose tolerance 
and GLUT4 protein content were similar between diet-matched ERαKOism and WT male 
mice, suggesting that skeletal muscle ERα function in the regulation of glucose 
homeostasis is critical in females, but not in males. Furthermore, we found that total 
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body fat, gonadal fat, and gain in fat mass over time were not greater in diet-matched 
ERαKOism than WT mice, yet skeletal muscle of female ERαKOism mice, regardless of 
diet, exhibited greater expression of key pro-inflammatory cytokines, TNF, IL6, and 
chemokines CCL2, CCL3 compared to WT mice. Collectively, our data suggest that 
induced ablation of skeletal muscle-specific ERα in adult female mice increased the 
susceptibility to develop skeletal muscle inflammation and reduced GLUT4 protein 
levels, independent of adiposity, which may have contributed to the glucose intolerance 
under chronic lipid overload. 
Our findings support the notion that estrogens play a role in preventing local 
inflammation in the skeletal muscle. Similar ideas have been seen in literature using 
other models and other tissues. For instance, exogenous estradiol treatment for 1 
month has been shown to lower the expression of circulating serum pro-inflammatory 
cytokines IL1B, IL8, and IL12 in young regularly menstruating obese women (Al-Safi et 
al., 2015). Conversely, reduced circulating estrogens by ovariectomy in mice results in 
greater expression of intraabdominal adipose pro-inflammatory markers CCL2, F4/80, 
CD11C, IL12p40, and IFNγ than sham-operated mice at 26 weeks post-surgery, which 
is associated with lower insulin sensitivity but is not due to excess adiposity (Vieira 
Potter et al., 2012). ERα has been shown to mediate estrogen-induced reduction of 
local inflammation in lung tissue, as indicated by the greater expression of ICAM-1 and 
TNF in global ERαKO mice compared to WT mice (Vegeto et al., 2010). Our results are 
also similar with previous studies, which have shown that global ERαKO and 
conventional skeletal muscle-specific ERαKO (MERKO) mice exhibit increased 
expression of pro-inflammatory markers, TNF and p-JNK in skeletal muscle; although, 
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global ERαKO and MERKO mice also display greater visceral adiposity than WT mice 
(Ribas et al., 2010, 2016). Indeed, elevated levels of TNF, IL6, and CCL2 are 
associated with lipid-induced insulin resistance and are consistently observed in skeletal 
muscle of non-diabetic obese insulin resistant and Type 2 diabetic individuals (Khan et 
al., 2015; Wu & Ballantyne, 2017). Moreover, studies in myocytes have demonstrated 
that elevated TNF and CCL2 expression further increases skeletal muscle infiltration of 
immune cells, which originates from intermuscular and perimuscular adipose depots 
(Wu & Ballantyne, 2017). These local skeletal muscle pro-inflammatory factors are 
known to exert paracrine effects, which results in decreased insulin signaling and 
glucose uptake (Wu & Ballantyne, 2017). Taking this into consideration, our data, which 
show that ex vivo skeletal muscle glucose uptake is similar between ERαKOism mice and 
WT mice, may be attributed to the loss of paracrine effects due to the nature of the 
experiment. 
Our data also indicate that CXCL1 expression is higher in skeletal muscle of 
female ERαKOism than WT mice, and this upregulation of CXCL1 may have contributed 
to the regulation of adiposity. A previous study has demonstrated that visceral and 
subcutaneous fat mass as well as body fat percentage are lower in mice with 
overexpressed skeletal muscle-specific CXCL1 compared to WT mice (Pedersen, 
Olsen, Pedersen, & Hojman, 2012). Indeed, our findings suggest that induced ablation 
of skeletal muscle-specific ERα in adult female mice does not exacerbate body mass 
and fat mass gain over the 12-week HFD treatment period. However, ERα appears to 
modulate CXCL1 expression in a cell-specific manner. In contrast to our findings in 
skeletal muscle, ERα has been documented to regulate CXCL1 in uterine epithelial 
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cells, such that inhibition of ERα decreases CXCL1 expression (Hickey, Fahey, & Wira, 
2013). Thus, future studies need to consider the possible regulation of CXCL1 
expression by estrogens in skeletal muscle. 
Previous studies have suggested that skeletal muscle mitochondrial function is 
important for maintaining insulin sensitivity (E. J. Anderson et al., 2009; Fisher-Wellman 
& Neufer, 2012) and that skeletal muscle ERα may be critical for maintaining 
mitochondrial function (Ribas et al., 2016). Specifically, insulin resistance can develop 
as a result of elevations in mitochondrial H2O2 levels, a major form of reactive oxygen 
species (ROS) in mitochondria, and a reduction in mitochondrial respiratory capacity, 
which can occur with chronic overnutrition (E. J. Anderson et al., 2009; Fisher-Wellman 
& Neufer, 2012). ERα is thought to regulate mitochondrial function by direct and indirect 
mitochondrial DNA-encoded gene transcription of several Complex I-V subunits in the 
electron transport system (Klinge, 2017). For instance, MCF-7 (ERα positive) breast 
cancer cells have mtDNA containing estrogen response element-like sequences, which 
ERα binds to in the presence of estradiol, with a dose- and time-dependent increase in 
binding affinity (J. Chen et al., 2009; Jin Q. Chen et al., 2004). ERα has also been 
reported to induce the transcription of certain mtDNA-encoded Complex I-V subunits in 
the electron transport system (ETS) (J. Chen et al., 2009; Jin Qiang Chen et al., 2005). 
Studies in MCF-7 breast cancer cells and H1793 lung adenocarcinoma cells have also 
demonstrated that ERα interacts with the estrogen response element-like sequence on 
nuclear respiratory factor-1 (NRF-1) (Mattingly et al., 2008), a nuclear transcription 
factor known to directly increase the expression of key nuclear DNA-encoded subunits 
in ETS (Scarpulla, 2012). NRF-1 also indirectly upregulates the expression of several 
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mtDNA-encoded subunits in ETS via activation of Transcription Factor A, Mitochondrial 
(TFAM) (Scarpulla, 2012).  A recent study has also demonstrated that ablation of 
skeletal muscle ERα (MERKO mice), where ERα function is lost during embryonic 
development, leads to a reduction insulin sensitivity and impairment in aspects of 
mitochondrial function, specifically mitochondrial fission and fusion dynamics, 
mitochondrial calcium retention capacity, and total ROS (mitochondrial and non-
mitochondrial) regulation by 7 months of age (Ribas et al., 2016). Furthermore, basal 
and maximal respiratory capacity, ATP synthesis, and palmitate oxidation rate are 
drastically (~50%) lower in C2C12 myotubes transduced with ERαshRNA compared to 
scramble myotubes (Ribas et al., 2016). In contrast, our data indicate that induced 
ablation of skeletal muscle ERα in adult female and male mice does not affect 
mitochondrial function. Mitochondrial respiratory capacity, H2O2 emission potential, ATP 
production rate, and OXPHOS efficiency in the presence of carbohydrate and fatty acid 
substrates in permeabilized fibers of female and male ERαKOism mice are not 
significantly different from diet-matched WT mice, even after chronic HFD. Our data 
suggest that fat oxidation is not reduced in ERαKOism mice, which may also explain why 
adiposity is not negatively affected in female and male ERαKOism mice. Energy 
expenditure is also unaltered in female ERαKOism mice and is only slightly increased in 
male ERαKOism mice at ~8 months of age. In line with our inducible ERα knockout 
mouse model, ERα knockdown in human myotubes isolated from adult healthy and 
obese-insulin resistant women only minimally reduces ATP production rates. Overall, 
our findings highlight that skeletal muscle ERα action in adult mice is not critical for 
maintaining adiposity and skeletal muscle mitochondrial function. We speculate that the 
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loss of skeletal muscle ERα function is not the primary mechanism, which underlies the 
increased susceptibility for excess adiposity associated with natural and surgical 
menopause. 
The results of the present study are not likely due to a meaningful compensatory 
increase in ERβ expression. Although, ERβ expression is higher in skeletal muscle of 
female ERαKOism than WT mice, ERα expression is several thousand-fold higher than 
ERβ. At present, whether GPER is a true estrogen receptor is still unclear (Levin, 
2009a), thus we did not assess GPER expression in our mice.  
Our findings are largely in contrast to previous studies, which have documented 
that global ERαKO and conventional skeletal muscle-specific ERαKO (MERKO) mice on 
control (low fat) diet display greater gonadal adiposity, systemic and local skeletal 
muscle insulin resistance, and altered mitochondrial health (R. Barros et al., 2009, 
2006, Ribas et al., 2010, 2016). Given that global ERαKO and MERKO mice (which are 
built using the muscle creatine kinase promoter to drive Cre expression) are generated 
in a manner where ERα function is ablated during the embryonic stage of development, 
the disparity between our data and previous findings suggest that ERα is essential for 
development, but not nearly as critical for maintaining metabolic function post-
development. Several lines of evidence support this observation. First, estrogens are 
known to play major roles in cell proliferation and organ differentiation during fetal 
development (Bondesson, Hao, Lin, Williams, & Gustafsson, 2015; Kaludjerovic & 
Ward, 2012), including skeletal muscle (Byrne et al., 2010). One study on ovine skeletal 
muscle development has shown that during the transition from late fetal period to 1-3 
days postpartum, muscle oxidative capacity increases in conjunction with the 
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upregulation of a multitude of genes, including those that contained ERα cis-regulatory 
motifs (Byrne et al., 2010). Second, reduced estrogen action alters fetal developmental 
programming (Abbott, Padmanabhan, & Dumesic, 2006) and affects metabolic 
homeostasis that manifests later in life. A recent study has documented that 3-year old 
offspring of pregnant baboons injected with the aromatase inhibitor, letrozole, exhibit 
insulin resistance, as reflected by greater fasting glucose, fasting insulin, glucose 
intolerance, and HOMA-IR than both untreated offspring and offspring of baboons 
injected with letrozole plus estradiol (Maniu et al., 2016). Insulin resistance persists in 
offspring of baboons injected with letrozole through 6 years of age (Pepe et al., 2016). 
We speculate that skeletal muscle ERα is critical for mediating estrogen function during 
fetal developmental programming given that ERα ablation in global ERαKO and 
MERKO mice also results in marked insulin resistance (Ribas et al., 2010, 2016). Third, 
adaptive/redundant mechanisms can maintain homeostasis. Researchers have 
previously proposed that such mechanisms may explain disparities between loss-of-
function since birth and loss-of-function in adult mice (Luquet, Perez, Hnasko, & 
Palmiter, 2005; Qiu et al., 2017). For example, in vivo neonatal ablation of neuropeptide 
Y (NPY)/agouti-related protein (AgrP) in neurons of mice results in slightly lower food 
intake than the age-matched WT, whereas induced in vivo NPY/AgrP ablation in 
neurons of adult (12-week old) mice leads to a major reduction in food consumption and 
an immediate ~20% drop in body mass in 2 days (Luquet et al., 2005). The authors 
have suggested that a network-based compensatory mechanism may be present in 
neonates; albeit, the nature of adaptive changes are still unknown (Luquet et al., 2005). 
In the present study, we speculate that estrogen receptor-independent mechanisms 
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may have played a role in maintaining adiposity and skeletal muscle mitochondrial 
function in adult ERαKOism mice. Indeed, a recent study has demonstrated that 
ovariectomy reduces skeletal muscle mitochondrial respiratory capacity and increases 
mitochondrial H2O2 emission potential, whereas 17β-estradiol can localize in 
mitochondrial membranes in the absence of ERα and functions to enhance membrane 
fluidity, which in turn, optimizes mitochondrial function and redox homeostasis (Torres 
et al., 2018). Future studies are needed to directly define adaptive or redundant 
mechanisms that occur with the loss of skeletal muscle ERα function in adults. 
Collectively, our data suggest that skeletal muscle ERα in adult female mice is 
critical for preventing excessive elevations in skeletal muscle inflammation and 
preserving GLUT4 levels, which in part, contribute to the maintenance of glucose 
tolerance under chronic lipid overload. Furthermore, induced ablation of ERα in adult 
skeletal muscle does not exacerbate fat mass gain nor detrimentally affect 
mitochondrial function. These findings suggest that adaptive or redundant mechanisms 
are likely established by the time ERα function is lost in adult skeletal muscle. Indeed, 
our work also brings light to the importance of investigating the function of genes 





Table 1. Tissue Mass of  WT and ERαKOism Mice after Chronic (12-week) HFD 
  Females Males 
  WT-CD WT-HFD KO-CD KO-HFD WT-CD WT-HFD KO-CD KO-HFD 
Heart (mg) 118 ± 4 122 ± 3 114 ± 4 119 ± 7 143 ± 6 143 ± 8 139 ± 6 150 ± 15 
Liver (mg) 1186 ± 66 1257 ± 71 1239 ± 75 1138 ± 96 1557 ± 179 2506 ± 455 1824 ± 221 1717 ± 254 
Gonadal fat (mg) 1037 ± 115 2908 ± 345* 1317 ± 209 2960 ± 458* 1553 ± 87 3460 ± 250* 1898 ± 190 2829 ± 100*† 
Data are means ± SEM. *Main effect of diet, p<.05 within each sex. 
†
Significant difference between male WT-HFD and ERαKO
ism
-








Figure 1. Characterization of a novel inducible skeletal muscle-specific ERαKO mouse  
(A) Mice that possessed ERαflox/flox x HSA-MCM were used in this study. Exon 3 of ESR1 was deleted upon Cre 
activation, subsequently inactivating ERα function. (B-C) Recombination of ESR1 in skeletal muscle of vehicle-injected 
(WT) and tamoxifen-injected ERαflox/flox x HSA-MCM (ERαKOism) mice. (D) Esr1 and Esr2 mRNA expression normalized 
to 18s rRNA in gastrocnemius of female WT and ERαKOism mice. (E) Esr1 and Esr2 mRNA expression normalized to 
18s rRNA in gastrocnemius of male WT and ERαKOism mice. (F) ERα protein content in tibialis anterior of WT and 
ERαKOism mice. Data are means ± SEM. *Simple main effect of diet, p<.05. †Main effect of genotype, p<.05. Females: 





Figure 2. Induced ablation of skeletal muscle ERα in adult mice had no effect on adiposity 
(A,I) Body mass, (B,J) Change in body mass over time, (C,K) Total fat mass, (D,L) Change in total fat mass over time, 
(E,M) Total lean mass, (F,N) Change in total lean mass over time, (G,O) Average food intake over the course of the 
study, and (H,P) Average food intake per week of female (A-H) and male (I-P) WT and ERαKO
ism
 mice fed a control 
(low fat) diet (CD) or high fat diet (HFD). Data are means ± SEM. *Main effect of diet, p<.05. 
†
Main effect of genotype, 
p<.05. Females: n=8/group, Males: n=6-8/group. 
WT-CD F 
WT-HFD F 











Figure 3. Induced ablation of skeletal muscle ERα in adult female mice had no effect on respiratory exchange ratio, 
whole body O2 consumption, and CO2 production 
Whole body calorimeter measurements of respiratory exchange ratio (RER), whole body O2 consumption (VO2), and 
CO2 production (VCO2) at (A) baseline, (B) during the diet switch (first 2-3 days of HFD), and (C) after chronic HFD. 
Data are means ± SEM. *Main effect and simple main effects of diet, p<.05. Females: n=7-10/group. 






Figure 4. Induced ablation of skeletal muscle ERα in adult female mice had no effect on energy expenditure and 
spontaneous cage activity 
Whole body calorimeter measurements of energy expenditure (H) and activity counts at (A) baseline, (B) during the 
diet switch (first 2-3 days of HFD), and (C) after chronic HFD. Data are means ± SEM. *Main effect of diet, p<.05. 
Females: n=7-10/group. 






Figure 5. Induced ablation of skeletal muscle ERα in adult male mice minimally altered whole body O2 consumption and 
CO2 production after chronic HFD 
Whole body calorimeter measurements of respiratory exchange ratio (RER), whole body O2 consumption (VO2), and 
CO2 production (VCO2) at (A) baseline, (B) during the diet switch (first 2-3 days of HFD), and (C) after chronic HFD. 
Data are means ± SEM. *Main effect of diet, p<.05. 
†
Main effect and simple main effects of genotype, p<.05. Males: 
n=5-8/group.  






Figure 6. Induced ablation of skeletal muscle ERα in adult male mice minimally altered energy expenditure after 
chronic HFD 
Whole body calorimeter measurements of energy expenditure (H) and activity counts at (A) baseline, (B) during the 
diet switch (first 2-3 days of HFD), and (C) after chronic HFD. Data are means ± SEM. *Main effect of diet, p<.05. 
†
Main effect and simple main effects of genotype, p<.05. Males: n=5-8/group.  






Figure 7. Induced ablation of skeletal muscle ERα in adult female mice increased the susceptibility to develop 
glucose intolerance after chronic HFD treatment that is associated with reduced skeletal muscle GLUT4 protein 
content 
Glucose tolerance of female and male WT and ERαKO
ism
 after (A) acute HFD (1 week) and (B) chronic HFD (11 
weeks). Females: n=6-9/group, Males: n=5-7/group. Ex vivo basal and insulin-stimulated skeletal muscle glucose 
uptake in (C) extensor digitorum longus (EDL) and (D) soleus muscles of female WT and ERαKO
ism
 mice after 
chronic HFD. Females: n=6-8/group. Western blots for tibialis anterior muscle protein content of (E) glucose 
transporter-4 (GLUT4), (F) hexokinase II, and (G) glycogen synthase. Females: n=5/group, Males: n=4-/group. Data 
are means ± SEM. *Main effect of diet, p<.05. 
†





Figure 8. Induced ablation of skeletal muscle ERα in adult female mice alters the gene expression of inflammatory 
markers in skeletal muscle 
Key pro-inflammatory cytokines and chemokines in gastrocnemius of female WT and ERαKO
ism
 after chronic HFD. 
mRNA expression was measured by real-time PCR and normalized to 18s rRNA. TNF = tumor necrosis factor; IL6 = 
interleukin-6; IL1B = interleukin-1β; CXCL2 = chemokine (C-X-C motif) ligand 2; CXCL1 = chemokine (C-X-C motif) 
ligand 1; CCL3 = Chemokine (C-C motif) ligand 3; Chemokine (C-C motif) ligand 2. Data are means ± SEM. *Main 
effect of diet, p<.05. 
†





Figure 9. Induced ablation of skeletal muscle ERα in adult mice did not alter mitochondrial respiratory capacity 
even after chronic HFD 
Oxygen consumption rate (JO2) in permeabilized muscle fibers of WT and ERαKO
ism 
CD- and HFD-fed female (A-
B) and male mice (C-D). Carbohydrate (pyruvate/malate/glutamate)-supported JO2 (A,C). Fatty acid (palmitoyl-
carnitine/palmitoyl-coA/l-carnitine)-supported JO2 (B,D). CI = Complex I; CII = Complex II; CI+II = Complex I + 
Complex II; CIV = Complex IV; Cyto c = cytochrome c; wt = weight. Data are mean ± SEM. *Main effect and 






Figure 10. Induced loss of skeletal muscle ERα in adult mice did not affect ATP production rate and OXPHOS 
efficiency 
ATP/O ratio in permeabilized muscle fibers of WT and ERαKO
ism 
CD- and HFD-fed female (A-C) and male mice 
(D-F) mice. ATP production rate (A,D), O2 consumption rate (B,E), and ATP/O ratio (C,F). Data are mean ± SEM 






Figure 11. Induced loss of skeletal muscle ERα in adult mice did not affect H2O2 emitting potential even after a chronic 
HFD 
H2O2 emission rate (JH2O2) in permeabilized muscle fibers of WT and ERαKO
ism 
CD- and HFD-fed female (A-C) and 
male mice (D-F). Succinate-supported H2O2 emission rate (A,D), fatty acid (palmitoyl-carnitine/palmitoyl-coA/l-
carnitine)-supported H2O2 emission rate (B,E) , and pyruvate (pyr)/carnitine (car)-supported H2O2 emission rate (C,F). 






Table 2. Subject Characteristics 
 
Healthy Obese-Insulin Resistant  
Sample size (N) 9 5 
Age (yrs) 24±1.6 41±3.6* 
Weight (kg) 62.1±2.0 112.9±5.3* 
BMI (kg/m
2
) 22.9±0.8 41.0±1.8* 
Insulin (mU/L) 5.4±0.6 15.3±1.5* 
Glucose (mg/dl) 86±7.8 96.4±4.34
*
 
HOMA IR 1.2±0.5 3.7±0.5* 
VO2max (ml/kg/min) 44.9±1.6 23.0±1.8* 









Figure 12. Knockdown of ERα in human myotubes from healthy and obese insulin-resistant subjects minimally 
affects basal O2 consumption and ATP production rates 
OCR = oxygen consumption rate; Oligo = oligomycin; FCCP = carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone; CRCR = cell respiratory control ratio; CII = Complex II; CIII = Complex III; CIV 
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Supplementary Figure 1. ERα (Esr1) mRNA expression across multiple tissues in WT mice and C2C12 myotubes 
G = gastrocnemius muscle; Q = quadriceps muscle; TA = tibialis anterior muscle; EDL = extensor digitorum longus; 






Supplementary Figure 2. ERα (ESR1) localizes in the nuclei 
Sample images of two-photon-second harmonic imaging of GFP-tagged ESR1-66kDa, ESR1-46kDa, and ESR1-36kDa 






Supplementary Figure 3. Induced ablation of skeletal muscle ERα in adult mice did not affect muscle 
contractility even after a chronic HFD 
Specific force (A,D), absolute force (B,E), and fatigue development (C,F) of female WT and ERαKO
ism 
mice 
(A-D) and male WT and ERαKO
ism 
mice (E-H). Data are mean ± SEM. 
 
 
Chapter 4: Summary, Clinical Significance, and Future Directions  
Summary 
 
The purpose of this dissertation was to investigate whether skeletal muscle ERα 
is critical for maintaining metabolic function under conditions of lipid overload. The 
approach in this study involved the generation of a novel inducible skeletal muscle-
specific ERα knockout mouse model. The model allowed us to determine the functions 
of skeletal muscle ERα in the regulation of glucose and lipid homeostasis without the 
confounding factors associated with development. The results indicated that induced 
ablation of skeletal muscle ERα did not affect adiposity, whole body oxygen 
consumption, energy expenditure, spontaneous cage activity, and glucose tolerance in 
female and male mice under low fat and acute high fat diet (HFD) treatments. 
Interestingly, skeletal muscle ERα ablation led to elevated expression of pro-
inflammatory cytokines and chemokines that was associated with reduced GLUT4 
protein content in skeletal muscle of female mice, which may have contributed to the 
glucose intolerance after chronic HFD treatment. In male mice, induced ablation of 
skeletal muscle ERα led to a subtle increase in energy expenditure after chronic HFD, 
despite no significant alterations in spontaneous cage activity. Finally, adiposity and 
indices of mitochondrial function, particularly respiratory capacity, oxidative 
phosphorylation efficiency, and H2O2 emission potential, in the presence of 
carbohydrate-derived and fatty acid substrates, were not affected by the loss of skeletal 
muscle ERα function in both female and male mice after chronic HFD. The function of 




assessed in an attempt to translate the findings from ERαKOism mice. Primary human 
skeletal muscle cells from healthy and obese-insulin resistant adult women were 
transduced with an adenovirus-driven ERαshRNA and differentiated into mature 
myotubes. The data indicated that ATP production rate was only minimally affected in 
ERα knockdown human myotubes from both healthy and obese-insulin resistant groups. 
Collectively, the results of this dissertation bring light to the functions of skeletal muscle 
ERα in the maintenance of glucose homeostasis and skeletal muscle inflammation. 
Importantly, these key findings were observed after ERα ablation in adult skeletal 
muscle and thus, were not confounded by developmental effects that are likely present 




Women and men with reduced estrogen action are at increased risk of gaining 
excess adiposity and developing insulin resistance; however, underlying mechanisms 
remain poorly defined, requiring a better understanding of estrogen-sensitive processes 
to either improve preventive approaches or develop appropriate treatment strategies. 
This dissertation showed that ERα in adult skeletal muscle mediates the protective role 
of estrogens against HFD-induced glucose intolerance in females by regulating skeletal 
muscle inflammation and preserving skeletal muscle GLUT4 levels. Future studies 
should be directed towards defining how skeletal muscle ERα influences mechanisms 
that regulate the expression of genes associated with inflammatory signaling.  
Interestingly, the results of this study also indicated that skeletal muscle ERα 




finding contradicted previous results using global ERαKO and conventional skeletal 
muscle-specific ERαKO mouse models, which documented that ERα ablation during the 
embryonic stage of development led to increased visceral adiposity and alterations in 
skeletal muscle mitochondrial health (Ribas et al., 2010, 2016). Similar results were 
found in fetal estrogen deficiency that resulted in altered developmental programming of 
mechanisms that regulate metabolic homeostasis during adulthood (Maniu et al., 2016; 
Pepe et al., 2016). ERα in adult skeletal muscle may not be as necessary for 
maintaining lipid homeostasis and mitochondrial function because of compensatory or 
redundant mechanisms that are likely established in adults. For example, a recent study 
in mice demonstrated that estradiol directly incorporates in the mitochondrial 
membrane, independent of ERα, decreasing membrane microviscosity, which in turn, 
optimizes mitochondrial function (Torres et al., 2018). The nature of these ERα-
independent mechanisms remain to be clearly elucidated and may serve as a 
foundation for future potential strategies that can decrease or eliminate the risk of 
excess adiposity and insulin resistance associated with reduced estrogen action by 







Future Directions and Limitations 
 
 Female ERαKOism mice exhibited increased expression of pro-inflammatory 
markers in skeletal muscle, reduced skeletal muscle GLUT4 protein content, and 
glucose intolerance after chronic HFD, implying loss of skeletal muscle ERα function 
may have increased the susceptibility to develop skeletal muscle insulin resistance in 
adult female mice exposed to a long-term HFD. However, ex vivo basal and insulin-
stimulated glucose uptake in the extensor digitorum longus and soleus muscles were 
similar between WT and ERαKOism mice, suggesting that detecting the role of skeletal 
muscle ERα in modulating in vivo glucose uptake may have been lost due to the nature 
of the ex vivo glucose uptake experiment. Future studies must consider measuring 
skeletal muscle insulin sensitivity in ERαKOism mice utilizing in vivo methods such as the 
hyperinsulinemic-euglycemic clamp or in vivo glucose uptake experiments.  
 The elevated mRNA expression of several known pro-inflammatory cytokines 
and chemokines in skeletal muscle of female ERαKOism mice also strongly suggested 
that induced ablation of skeletal muscle ERα increased the susceptibility to exhibit 
heightened skeletal muscle inflammation, independent of excess adiposity, in adult 
female mice. This is an important finding given that inflammation is often associated 
with increased adipose tissue and intramuscular fat accumulation (Wu & Ballantyne, 
2017), which was indeed observed in previous global ERαKO and conventional skeletal 
muscle-specific ERαKO mice (Ribas et al., 2010, 2016). Thus, further studies are 
required to confirm the mRNA expression data and comprehensively determine whether 
skeletal muscle inflammation is a primary consequence of the loss of skeletal muscle 




whether gene expression accurately parallels protein levels. Flow cytometry (Fink et al., 
2014), immunohistochemistry, or in situ hybridization experiments (Amsen, Visser, & 
Town, 2009) may reveal the type of immune cells that are excessively producing 
cytokines in skeletal muscle of female ERαKOism mice. Furthermore, future experiments 
are required to identify specific targets that are involved in the regulation of skeletal 
muscle inflammation, which have ESR1 binding sites in their promoter regions. Finally, 
determining whether systemic inflammation is affected in female ERαKOism mice can be 
addressed by flow cytometry experiments. 
Adiposity and mitochondrial function were not affected in ERαKOism mice in the 
present study whereas previously studied conventional skeletal muscle-specific ERαKO 
mice exhibited greater body fat, intramuscular fat accumulation, and altered 
mitochondrial health compared to WT mice (Ribas et al., 2016). ERαKOism mice were 
generated by crossing ERα-floxed mice with human skeletal actin-MerCreMer mice, 
which allowed the temporal ablation of ERα. On the other hand, the previous conditional 
skeletal muscle-specific ERαKO mice used to determine the role of skeletal muscle-
specific ERα in maintaining metabolic homeostasis were generated by crossing ERα-
floxed mice with muscle creatine kinase-Cre mice, which resulted in the loss of skeletal 
muscle ERα function during the embryonic stage of development. This inherent 
difference between mouse models, along with their divergent metabolic phenotypes at 
adulthood have led to the speculation that skeletal muscle ERα is essential for fetal 
programming, but not nearly as critical post-development for the regulation of lipid 
homeostasis and mitochondrial function. This hypothesis will need to be addressed 




with human skeletal actin-Cre mice (Collins et al., 2018) or by identifying 
compensatory/redundant mechanisms that are likely established in adult ERαKOism 
mice.  
Finally, the novel ERαKOism mouse model is a valuable tool; however, future 
studies must be conducted to determine the functions of skeletal muscle-specific ERα in 
humans. Aside from the phylogenetic differences between mice and humans, inbred 
mice in this study also lack the genetic variations of outbred mice and humans. 
Therefore, the mechanisms involved in disease susceptibility may be different between 
the two species. For instance, this dissertation showed that ERαKOism mice exhibited 
normal skeletal muscle mitochondrial respiratory capacity, ATP production rate, and 
OXPHOS efficiency; however, silencing ERα in human myotubes that were isolated 
from healthy and obese-insulin resistant women resulted in a subtle reduction in ATP 
production rate. Although both findings support the notion that induced ablation of 
skeletal muscle ERα does not lead to drastic impairments in mitochondrial respiration, 
future experiments can be directed towards verifying whether skeletal muscle ERα is 
important for mitochondrial respiration in human skeletal muscle derived from biopsies. 
To avoid the confounding effects of age, differences in respiratory capacity can be 
compared between skeletal muscle biopsies obtained from women treated with 
leuprolide acetate (a gonadotropin releasing hormone agonist that suppresses ovarian 
hormones) (Melanson et al., 2015; Shea et al., 2015), women treated with leuprolide 
acetate + estradiol, and women treated with leuprolide acetate + a selective estrogen 
receptor modulator (e.g. bazedoxifene or a future novel selective estrogen receptor 




2017). Additionally, ERαKOism mice exhibited elevated skeletal muscle inflammation 
under low fat and chronic HFD conditions. Given that estradiol treatment has anti-
inflammatory effects in obese women (Al-Safi et al., 2015) and menopause is 
associated with increased inflammation in certain tissues (Iyengar et al., 2015), ERα is 
likely a key regulator of skeletal muscle inflammation in women, but this remains to be 
tested.  
Collectively, these aforementioned studies can uncover direct targets that are 
regulated by ERα, which may lead to the discovery of safer and more effective 
strategies for preventing or treating excess adiposity and insulin resistance associated 
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